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The primary goal of novel anticancer drug design is to selectively target and kill the 
cancer cells, improving therapeutic efficacy while minimizing side effects. Lipid shell 
and polymer core drug delivery systems have received increasing attention due to the 
combinations of merits from liposomes and polymeric nanoparticles. In this work, the 
effects of different lipids used in nanoparticle preparation on their characteristics and 
in vitro performance were studied.  Nanoparticles of PLGA as the core and various 
lipids as the shell were produced by nanoprecipitation method. Transferrin was used as 
the targeting ligand. Series of characterization of the nanoparticles were carried out by 
laser light scattering (LLS) for particle size and size distribution, zeta potential 
analyzer for surface charge and field emission scanning electron microscopy (FESEM) 
for surface morphology. The presence of lipid layer on the surface of nanoparticles 
was confirmed by X-ray photoelectron spectroscopy (XPS). The structure of lipid shell 
and polymer core was visualized by transmission electron microscopy (TEM). The 
drug encapsulation efficiency (EE) of the docetaxel-loaded nanoparticles was 
measured by high performance liquid chromatography (HPLC). The size, surface 
charge and EE of the nanoparticles were found to be correlated to the lipid type and 
quantity. Moreover, in vivo pharmacokinetics study, complete blood count analysis 
and toxicity assessment through haematology assay and histological analysis of 
clearance organs were carried out in order to demonstrate the prospect of the 
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CHAPTER 1: INTRODUCTION 
  
1.1 General Background 
Cancer is one of the major devastating diseases. Currently available effective 
treatments include surgery, radiotherapy, chemotherapy, hormone therapy and 
immunotherapy, which are usually given in combinations (American Cancer Society, 
2010). Among them, chemotherapy has become the most promising treatment option 
with the help of advances in materials science and protein engineering. Novel 
nanoscale drug delivery devices and targeting approaches which may bring new hope 
to cancer patients are being extensively investigated (Peer et al. 2007). The primary 
goal of novel anticancer drug design is to selectively target and kill the cancer cells, 
improving therapeutic efficacy while minimizing the side effects (Moghimi et al., 
2005; Torchilin, 2010). 
Currently used pharmaceutical nanocarriers, such as polymeric nanoparticles (NPs), 
liposomes, micelles, and many others demonstrate a variety of useful properties, 
including long circulation in the blood and controlled drug released profile (Ferrari, 
2005). In the recent years, lipid shell and polymer core nanoparticles are gaining 
interest as they are able to combine the merits of both liposomal and nanoparticulate 
drug delivery systems (Chan et al., 2009; Salvador-Morales et al., 2009; Liu et al., 
2010). Doxil (Doxorubicin encapsulated liposome) was the first to get FDA approval 
in 1995 for the treatment of Kaposi‘s sarcoma and ovarian cancer (Wagner et al, 1994; 
Gottlieb et al, 1997; Salvador-Morales et al., 2009). Even though liposomes are highly 
biocompatible and are able to provide favourable pharmacokinetic profile, they have 
insufficient drug loading, faster drug release and storage instability. Meanwhile, 
nanoparticles can provide high drug encapsulation efficiency for hydrophobic drugs 
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and controlled drug release profile (Salvador-Morales et al., 2009; Liu et al., 2010). 
Therefore, lipid shell and polymer core nanoparticles with antitumor targeting would 
be an ideal nanoscale drug delivery system for hydrophobic drugs such as docetaxel 
and paclitaxel. 
Biodegradable polymers such as poly(D,L-lactic acid) (PLA), poly(D,L-lactic-co-
glycolic acid) (PLGA) and poly(3-caprolactone) (PCL) and their co-polymers 
diblocked or multiblocked with polyethylene glycol (PEG) have been commonly used 
to synthesize nanoparticles to encapsulate a variety of therapeutic compounds (Feng, 
2006). PEGylation, which refers to polyethylene glycol conjugated drugs or drug 
carriers, is essential for drug delivery devices to enhance both the circulation time and 
the stability (against enzyme attack or immunogenic recognition) (Davis, 2002; 
Danhier et al., 2010). DSPE-PEG2k (N-(carbonyl -methoxypolyethylene glycol-2000) -
1,2-distearoyl-sn-glycerol-3-phosphoethanolamine) , a lipid attached to PEG, is 
usually used to coat the outer surface of the liposome in order to get the PEGylation 
effects such as prolonged circulation half –life and reduced systemic clearance rate. 
These PEG-end groups may also be functionalized with specific ligands to target the 
specific sites of the cells, tissues and organs of interest (Chan et al., 2009; Liu et al., 
2010).  
Generally, malignant cells grow and divide faster than normal cells. In order to grow 
faster, they need to express more cell surface receptors for the transport of iron and 
nutrients (Hémadi et al, 2004). Transferrin receptor is one of the cell surface receptors 
and usually expressed more abundantly in malignant tissues than in normal tissues 
because of the higher iron demand for faster cell growth and division of the malignant 
cells (Vyas and Sihorkar , 2000; Li and Qian, 2002). Transferrin plays a pivotal role in 
the transportation of iron for the synthesis of haemoglobin (Li and Qian, 2002). Based 
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on this fact, transferrin can be potentially utilized as a cell marker for tumour 
detection. Therefore, transferrin–transferrin receptor interaction has been employed as 
a potential efficient pathway for cellular uptake of drugs, genes and nanocarriers (Li 
and Qian, 2002; Gomme, 2005). 
Docetaxel is a semi-synthetic taxane and one of the most effective anticancer drugs 
against a broad range of human malignancies (Montero et al., 2005).  It is approved for 
the treatment of patients with locally advanced or metastatic breast cancer or non-
small-cell lung cancer (NSCLC) and androgen-independent metastatic prostate cancer 
(Valero et al., 1995; Fossella et al., 2000; Petrylak, 2004).  However, because of poor 
solubility in water, docetaxel is formulated using Tween 80 (polysorbate 80) and 
ethanol (50:50, v/v) (Clarke et al., 1999). Tween 80 is responsible for acute 
hypersensitivity reactions which have been occurred in the majority of patients during 
phase I clinical trials (Fossella et al, 2000; Coors et al, 2005). In the view of this 
observation, there is a strong rationale for using nanocarrier to reformulate the 
docetaxel without using Tween 80. Docetaxel formulation without using potentially 
toxic adjuvant, Tween 80 (polysorbate 80), can be achieved by formulation of lipid 
shell and polymer core nanoparticles. This formulation can further be modified by 
conjugation with transferrin to achieve active targeting property. 
 
1.2 Objectives and Thesis Organization 
In this thesis, formulations of lipid shell and polymer core nanoparticles are developed 
for the clinical administration of docetaxel. At the same time, the effect of different 
lipids used in nanoparticle preparation on their characteristics and in vitro performance 
is studied. Moreover, in vivo pharmacokinetic study, complete blood count analysis 
and toxicity assessment through haematology assay and histological analysis of 
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clearance organs are carried out in order to demonstrate the prospects of the 
formulation as drug delivery system.  
The thesis is made up of seven chapters. The first chapter is to provide a brief 
introduction including a general background and objectives of the project. In Chapter 
2, a literature review on cancer and cancer chemotherapy, and the concept and 
formulations of drug delivery system is provided. The strategies applied for targeted 
drug delivery system is also clearly described in this chapter. Then, the synthesis and 
characterization of lipid shell and polymer core nanoparticles (LPNPs) are discussed in 
Chapter 3 while the synthesis and characterization of transferrin conjugated lipid shell 
and polymer core nanoparticles are discussed in Chapter 4. In Chapter 5, in vitro 
cellular study of transferrin conjugated LPNPs is performed using MCF7 human breast 
adenocarcinoma cells. In Chapter 6, in vivo pharmacokinetics, complete blood count 
and blood biochemistry study using Sprague-Dawley rats are investigated to compare 
the LPNPs formulation and the commercial formulation (Taxotere
®
). Finally, 














CHAPTER 2: LITERATURE REVIEW 
 
2.1 Cancer and cancer chemotherapy    
Cancer is a group of diseases caused by uncontrolled growth and spreading of 
abnormal cells. It is the second most common cause of death in the United States, 
following cardiovascular diseases. Currently, one in four deaths in the United States 
and Europe is attributed to cancer (American Cancer Society, 2010; Albreht et al., 
2008). In fact, the emotional and physical suffering inflicted by cancer is more 
agonizing than death. Fortunately, the silver lining is that the cancer mortality rate for 
both male and female has declined in the United States during last two decades. It is 
believed that external factors (e.g., tobacco smoking, chemicals, radiation, and 
infectious organism) and internal factors (e.g., inherited mutations, hormones, and 
immune conditions) may act together (or sequentially) to initiate and promote 
carcinogenesis (Feng and Chien, 2003; American Cancer Society, 2010). 
 
2.1.1 Treatments of cancer 
Surgery, radiotherapy, chemotherapy, hormone therapy, biological therapy and 
targeted therapy are usually employed as treatments for cancer. These treatment 
modalities may be rendered alone or in combination, depending on the stage of cancer 
and other factors.  Surgery can be used to prevent, treat and diagnose cancer. The 
objective of conducting surgery in cancer treatment is to remove tumours or as much 
of the cancerous tissues as possible. For the more complicated cancer cases where 
possible treatments may be limited, palliative surgeries may be rendered which aim at 
improving the quality of life of the patients. On the other hand, chemotherapy, another 
type of cancer treatment, uses drugs to eliminate rapidly multiplying cancer cells. 
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Unfortunately, besides eliminating the cancer cells, rapidly multiplying hair follicle 
and stomach lining cells will also be affected, resulting in side effects like hair loss and 
stomach upset. In radiation therapy, certain types of energy are utilized to shrink 
tumours or eliminate cancer cells by damaging their DNA, stunting growth. Cancer 
cells are sensitive to radiation and typically die when treated. However, surrounding 
healthy cells can be affected as well. Fortunately, they are able to recover fully. Early 
detection and treatment are critical factors in determining the patient‘s prognosis. 
Therefore, regular screening examinations are becoming crucial in cancer prevention 
and treatment. Although it is difficult to predict who is at risk of developing cancer, it 
is undeniable that the incidence of cancer can be reduced by undergoing regular cancer 
screening, controlling tobacco smoking, alcohol usage, obesity and sun exposure, and 
having appropriate nutrition and physical activity (American Cancer Society, 2010). 
 
2.1.2 Anticancer drugs 
Chemotherapy is defined as the use of any medicine for treatment of any disease. 
Chemotherapy for cancer, however, is described as the use of chemotherapeutical 
agents to kill or control cancer cells. The combination of chemotherapy with other 
treatments has become the primary and standard treatments for cancers, as well as for 
other diseases caused by uncontrolled cell growth and invasion of foreign cells or 
viruses (Feng and Chien, 2003). 
Cancer chemotherapy was discovered by chance. During the 2nd World War, the US 
navy was exposed to nitrogen mustard gas accidentally. The alkylating agent was 
found to cause reduction in cell number of the bone marrow and lymphoid tissues. 
This agent was adapted for the clinical treatment of advanced lymphomas in 1943 
(Bishop, 1999). Over the following years, there have been hundreds of anticancer 
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agents available for clinical use; some are synthetic chemicals and some are natural 
extracts. Chemotherapeutic agents can be divided into few groups according to their 
mechanisms of action. Some of them are antimetabolites, alkylating agents, antimitotic 
agents and anthracyclines. 
Methotrexate is one of the most widely used antimetabolites that competitively inhibits 
dihydrofolate reductase (DHFR) which converts dihydrogenfolate (DHF) to 
tetrahydrofolate (THF). This prohibits the synthesis of folic acid, pyrimidine or purine 
for DNA/RNA. Methotrexate is a S-phase specific anticancer agent (Allegra et.al., 
1985; Blakley et.al., 1998).  Cyclophosphamide is a nitrogen mustard alkylating agent 
which covalently bond with DNA, inhibiting DNA replication and transcription. It is a 
prodrug which will transform to its active form in the liver. It is used in the treatment 
of a wide range of cancers including Hodgkin‘s disease, non-Hodgkin‘s lymphoma, 
various types of leukemia, multiple myeloma, neuroblastomas, adenocarcinomas of the 
ovary, and certain malignant neoplasms of the lung.  Antimitotic (anti-microtubular) 
agents include the naturally occurring vinca alkaloids (e.g. vincristine and vinblastine) 
and their semi-synthetic analogues (e.g. vinorelbine) and the taxanes (e.g. paclitaxel 
and docetaxol). They act on the microtubules, an essential part of the cytoskeleton of 
eukaryotic cells. The vinca alkaloids prevent the protein from polymerizing into 
microtubules by binding specifically to β-tubulin. In contrast, the taxanes prevent the 
microtubules from depolymerisation by binding to the β-tubulin subunits of the 
microtubules during the mitotic phase (Cutts, 1961; Kruczynski et al., 1998). The 
anthracyclines (eg. doxorubicin) are regarded as essential agents in combination 
chemotherapeutic regimens and have been successfully used in the first and second-
line treatments of metastatic diseases. The major mechanism contributing to their 
cytotoxicity against tumors remains unclear. However, it is widely acknowledged that 
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these compounds intercalate with DNA, thereby preventing DNA and RNA synthesis 
(Fornari et al., 1994).  
 
2.1.2.1 Docetaxel 
Docetaxel is an antineoplastic agent belonging to the taxoid family. It is a semi-
synthetic product made from extracts of the renewable needle biomass of yew plants. 
The chemical name for docetaxel is (2R,3S)-N-carboxy-3-phenylisoserine,N-tert-
butyl;-20-epoxy-1,2α,4,7β,10b,13α-hexahydroxytax-11-en-9-one4-acetate 2-benzoate, 
trihydrate. Docetaxel has the following structural formula (Montero  et al., 2005): 
 
 
Figure 1: Chemical structure of docetaxel (Montero et al., 2005) 
Docetaxel is a white to almost white powder and is practically insoluble in water. The 
diluent for the clinical formulation contains 13% ethanol. The commercial product of 
docetaxel, Taxotere
®
, is developed by the pharmaceutical company Sanofi-Aventis. 
Taxotere
®
 is available as 20 mg and 80 mg single-dose vials of concentrated 
anhydrous docetaxel in polysorbate 80 (Clarke et al., 1999). The figure of Taxotere
®
 is 
shown in Figure 2. The prepared solution is a clear brown-yellow colour which 
contains 40 mg docetaxel per mL of polysorbate 80 (Clarke et al., 1999). This high 
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concentration solution is to be diluted with 0.9% sodium chloride or 5% glucose before 
administration (Clarke et al., 1999).  
 




Oral bioavailability of docetaxel is around 8 % as docetaxel is a substrate for p-
glycoprotein (Sparreboom, 1996; Malingre et al., 2001). Moreover, first-pass 
elimination by cytochrome P450 (CYP) isoenzymes in the liver and/or gut wall may 
also attribute to the low oral bioavailability of docetaxel (CYP 3A4) (Shou et al., 1998; 
Malingre et al., 2001).  However, when docetaxel is co-administered with 
cyclosporine, bioavailability increased up to 90% which is almost comparable with 
intravenous (IV) administration of docetaxel. But, in practice, docetaxel is usually 
given intravenously as IV administration. In doing so, bioavailability is boosted to 
100%, making it better and more helpful to achieve dose precision (Clarke et al., 
1999). In order to evaluate the pharmacokinetics profile, 100 mg/m
2
 dosages of 
docetaxel is given over one-hour infusions every three weeks in phase II and III 
clinical studies (Clarke et al., 1999). 
Docetaxel was shown to have 94-97 % plasma protein binding after IV administration 
(Extra et al., 1993). Docetaxel is mainly bound to alpha 1 acid glycoprotein, 
lipoproteins, and albumin. Among them, alpha 1 acid glycoprotein is the main 
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determinant of docetaxel's plasma binding variability. Docetaxel was unaffected by the 
polysorbate 80 which is used in its storage medium. Docetaxel interacted little with 
erythrocytes (Urien et al., 1996; Clarke et al., 1999).  
For the concentration-time profile of docetaxel, a n initial relatively rapid decline α 
half-life is observed after about 4.5 minutes while β half-life and γ half-life are 
observed after 38.3 minutes and 12.2 hours respectively. The initial rapid decline of α 
half-life is caused by distributed to peripheral compartments and β half-life and γ half-
life are the result of slow efflux of docetaxel from these compartments (Pazdur et al., 
1993; Clarke et al., 1999). The mean total body clearance of docetaxel is 21 L/h/m
2 
for 
the administration of 100 mg/m² dosage over a one hour infusion and the Cmax of 
docetaxel was around 4.15 ± 1.35 mg/L (Pazdur et al., 1993; Clarke et al., 1999; Baker 
et al., 2004).  Moreover, it was also found that docetaxel demonstrated a linear 
pharmacokinetics profile which implied that an increased dosage of docetaxel would 
result in a linear increase of the area under concentration-time curve (AUC) and peak 
concentration (Cmax) (Bissery et al., 1991; Gligorov and Lotz, 2004; McGrogan et al., 
2008). Hence, the dose of docetaxel used is directly proportional to plasma 
concentration and it can be used to predict the various determinants of 
pharmacokinetics profile when used together with different dosage regimes. Docetaxel 
is eliminated in both the urine and faeces (Pazdur et al., 1993; Marlard et al., 1993).  
Pharmacodynamics 
Like other taxanes, docetaxel stabilises structures which contains microtubule, causing 
cytotoxic effects in rapidly dividing cells, particularly during mitosis (Diaz and 
Andreu, 1993; Montero et al., 2005). Docetaxel binds to microtubules reversibly with 
high affinity and this binding stabilises microtubules and prevents depolymerisation at 
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the plus end of the microtubule that leads to initiation of apoptosis (Yvon et al., 1999; 
Montero et al., 2005) (Figure 3). Apoptosis is also encouraged by the phosphorylation 
of bcl-2 oncoprotein which is required to inhibit cell death (Haldar et al., 1997).  
 
Figure 3: Effect of docetaxel on microtubule function (Montero et al., 2005). 
Therapeutic applications 
Docetaxel was first approved in 1996 for the treatment of breast cancer which is 
refractory after anthracycline-based chemotherapy (Valero et al., 1995; Ravdin et al., 
1995; Hong et al., 2002) and later approved for stage IIIB or IV non-small-cell lung 
cancer which is refractory for platinum-based therapy (Fossella et al., 2000; Shepherd 
et al., 2000). Moreover, it has been shown that docetaxel combined with 
corticosteroids or estramustine can increase survival in metastatic androgen-
independent prostate cancer (Petrylak 2004; Tannock et al., 2004). Furthermore, 
docetaxel has been approved for use as an adjuvant in therapy for the early, high-risk 
breast cancer (Martin et al., 2003). 
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Adverse side effects  
Docetaxel is a chemotherapeutic agent and it can damage mechanisms that are 
essential to cell growth. As with all chemotherapy, the actions of the chemotherapeutic 
agents are not specifically aimed at the tumour cells and therefore can also adversely 
affect the ‗healthy‘ cells, resulting in drug-related side effects. The adverse effects 
associated with the use of docetaxel include neutropenia, hypersensitivity reactions, 
fluid retention, nail toxicities, neuropathy, alopecia and asthenia. Docetaxel is 
contraindicated in those known to be hypersensitive to it (and also paclitaxel or 
polysorbate 80), and in those with a neutrophil count less than 1500 cells/mm
3
 
(Shepherd et al., 2000; Fossella et al., 2000; O‘Shaughnessy et al., 2002).  
 
2.1.3 Limitations of traditional chemotherapy 
One of the problems of traditional chemotherapy is the dosage form and toxicity of the 
substances used. As most of the anticancer drugs are highly hydrophobic, solubilizers 
or adjuvants are needed to increase the solubility of anticancer drugs. For example, 
paclitaxel which contains some benzene rings and hydrophobic structures has very low 
solubility of less than 0.5 mg/ml. Therefore, the dosage form available for clinical 
administration of paclitaxel comes with Cremophor EL and dehydrated alcohol as 
adjuvant (Hennenfent and Govindan, 2006). The chemical structure of Cremophor EL 
(polyoxyethyleneglycerol triricinoleate 35) is shown in Figure 4 (Gelderblom et al., 
2001). Although Cremophor EL is used as a carrier for hydrophobic drugs, including 
cyclosporine and diazepam, it is rather toxic and can cause serious side effects such as 
hypersensitivity reaction, nephrotoxicity, peripheral neuropathies, and cardiotoxicity 
(Weiss et al., 1990; Gelderblom et al., 2001; Hennenfent and Govindan, 2006; Feng et 
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al., 2007). Hence, Taxol
®
, a commercial form of paclitaxel, can only be administered 
as an injection or infusion in a hospital setting. 
 
 
Figure 4: The chemical structure of Cremophor EL (Gelderblom et al., 2001). 
 
Another limitation of traditional chemotherapy is the drug resistance and 
bioavailability of the substances used. P-glycoprotein (P-gp) exists in the cell 
membrane and serves as a kind of efflux pump that can prevent drugs and other toxic 
substances from entering cells (Gatmaitan and Arias, 1993). P-gp is widely distributed 
in many tissues, such as gastro-intestinal tract, kidney and blood brain barrier. It has 
been found that paclitaxel has a rather high affinity for P-gp transporter, limiting its 
bioavailability for therapeutic effect. In addition, when drugs are administered orally, 
they have to withstand metabolic barriers before reaching the systemic circulation. 
This process is called first-pass metabolism and it can take place in liver and intestine 
(Feng et al., 2007). The main enzyme involved in that process is cytochrome P450 
(CYP) which consists of 18 families and 43 subfamilies. It is said that 75% of total 
metabolic process in human body is attributed to CYP (Malingre et al., 2001; 
Danielson, 2002). Therefore, CYP, P-gp and other multi drug resistance proteins 
(MRP) usually act together to lower the oral bioavailability of most anticancer drugs 
(Malingré et al., 2001; Varma et al., 2003). 
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Another biological barrier for anticancer drug delivery is the high plasma protein 
binding effect happening once the drugs enter the physiological system.  Plasma 
protein binding is part of the opsonisation process. The opsonin proteins present in the 
blood serum would quickly bind to the drug which would be detected as foreign 
material, allowing macrophages of the mononuclear phagocytic system (MPS) to 
easily recognize and remove the drug before they can perform their designed 
therapeutic function. The common opsonins are immunoglobulins and C3, C4, and C5 
of the complement system as well as other blood serum proteins such as laminin, C-
reactive protein, fibronectin and type I collagen (Frank and Fries, 1991; Johnson, 
2004). This mononuclear phagocyte system (MPS) is also known as the reticulo-
endothelial system (RES). The MPS involves macrophages (of liver, spleen, lung and 
lymph nodes) and monocytes (of blood stream) which have the ability to remove 
opsonised foreign material within seconds of intravenous administartion (Gref et al., 
1994; Müller et al., 1997; Hume, 2006). In general, the opsonization of hydrophobic 
material has been shown to occur more quickly than hydrophilic material due to the 
enhanced adsorbance of blood serum proteins on their surfaces (Carstensen et al., 
1992; Norman et al., 1992). Therefore, in order to get the desired pharmacokinetics 
profile (defined as the release of a sufficient quantity of drugs at the right time), the 
correct location within sufficient time frame, the solubility, stability and permeability 
of drugs become crucial factors.  
 
2.1.4 Anatomical, physiological and pathological considerations 
Because of the differences in the structure and physiology of normal and tumor tissues, 
it is possible to design the desired drug delivery systems that facilitate tumor-specific 
delivery of the anticancer drug. As mentioned above, most of the conventional 
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anticancer agents are distributed non-specifically in the body and can lead to systemic 
toxicity associated with serious side effects. Hence, the development of novel drug 
formulation aimed at targeting the tumor site by exploiting the nature of tumor 
microenvironment is becoming the important factor. 
(1) Enhanced permeability and retention (EPR) 
The tumor microenvironment has a lot of differences compared with normal tissues. 
These differences include oxygenation, perfusion, vascular abnormalities, pH and 
metabolic states. For a small solid tumor, oxygen and nutrients can reach the centre of 
the tumor by simple diffusion. When the tumor becomes larger, a state of hypoxia 
occurs, initiating angiogenesis which can lead to various abnormalities such as high 
proportion of proliferating endothelial cells, pericyte deficiency and aberrant basement 
membrane formation (Danhier et al., 2010). These vessels from tumor tissues are much 
more permeable than those of normal ones. Therefore, the nanocarriers for anticancer 
drugs or drug molecules can extravasate and accumulate in the interstitial space of 
tumors. The sizes of the endothelial pores are varied from 20 nm to 1000 nm (Danhier 
et al., 2010). Furthermore, the lack of functioning lymphatic vessels in tumors 
contributes to the inefficient drainage of extravasated nanocarriers or macromolecules 
from the tumor tissues leading to particles retaining more effectively in interstitial 
spaces of the tumors. This passive phenomenon is called ‗Enhanced Permeability and 
Retention (EPR) effect‘ (Figure 5) (Maeda et al., 2000 & 2001; Danhier et al., 2010). 
(2) Extracellular pH 
The extracellular pH of the tumor tissues is relatively lower than that of normal tissue. 
The measured extracellular pH of most solid tumors is between 6.0 and 7.0 whereas in 
normal tissues, the extracellular pH of is around 7.4 (van Sluis et al., 1999; Cardone, et 
al., 2005). The acidity of tumor interstitial fluid is mainly attributed to the high 
 16 
 
glycolysis rate in hypoxic cancer cells. This can lead to the idea of the development of 
pH-sensitive liposomes (Yatvin et al., 1978; Drummond et al., 2000).  
  
 
Figure 5: Differences between normal and tumor tissues that show the passive 
targeting of nanocarriers by the EPR effect.  
A. Normal tissues with linear blood vessels which are supported by pericytes. Collagen 
fibres, macrophages and fibroblasts are in the extracellular matrix. Lymph vessels are 
noted.  
B. Tumor tissues with defective blood vessels, sac-like formations and fenestrations. 
The extracellular matrix has more collagen fibres, macrophages and fibroblasts than in 
normal tissue. There is no lymph vessel (Danhier et al., 2010). 
 
2.1.5 Tumor Targeting 
The concept of tumor targeting dates back to 1906 when Ehrlich first imagined the 
―magic bullet‖ (Ehrlich, 1960; Danhier et al., 2010). The specific tumor targeting is 
aimed to better profiles of pharmacokinetics and pharmacodynamics, improve 
specificity, increase internalization and intracellular delivery and lower systemic 
toxicity.  In fact, the proper target for the disease, the proper drug to treat the disease 
effectively and the way to deliver the drug to the intended areas are the challenging 
factors of targeting. Tumor targeting can be classified into ―passive targeting‖ and 
―active targeting‖. Active targeting cannot be separated from the passive because it 
occurs only after passive accumulation in tumors (Bae, 2009; Danhier et al., 2010). 
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2.1.5.1 Passive targeting  
Passive targeting consists of the transport of nanocarriers through leaky tumor 
capillary fenestrations into the tumor interstitiumand cells. Selective accumulation of 
nanocarriers and drug then occurs by the EPR effect (Figure 6 and 7A) (Haley and 
Frenkel, 2008). The EPR effect is now becoming the gold standard in cancer-targeting 
drug design (Maeda et al., 2009). Indeed, EPR effect is applicable in almost all rapidly 
growing solid tumors with the exception of hypovascular tumors such as prostate 
cancer or pancreatic cancer (Unezak et al., 1996; Maeda et al., 2009).  
 
 
Figure 6: Visualization of extravasation of PEG-liposomes. A. Extravasation of PEG-
liposomes with 126 nm in mean diameter from tumor microvasculature was observed. 
Liposome localization in the tumor was perivascular. B. In normal tissue, extravasation 
of PEG-liposomes with 128 nm in mean diameter was not detected. Only fluorescent 
spots within the vessel wall were observed (Unezaki et al., 1996).  
 
 
The EPR effect will be optimal if the nanocarriers have the following properties: (i) 
The ideal nanocarrier size should be much less than 400 nm in order to efficiently 
extravasate from the fenestrations in leaky vasculature. On the other hand, nanocarrier 
size should be larger than 10 nm in order to avoid the filtration by the kidneys. (ii) The 
charge of the particles should be neutral or anionic for efficient evasion of the renal 
elimination. (iii)The nanocarriers should evade the immune surveillance and circulate 
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for a long period. Indeed, they must be hidden from the reticulo–endothelial (RE) 
system, which destroys any foreign material through opsonisation followed by 
phagocytosis (Malam et al., 2009; Gullotti and Yeo, 2009).  
 
 
Figure 7: A. Passive targeting of nanocarriers. (1) Nanocarriers reach tumors 
selectively through the leaky vasculature surrounding the tumors. (2) Schematic 
representation of the influence of the size for retention in the tumor tissue. Drugs alone 
diffuse freely in and out the tumor blood vessels because of their small size and thus 
their effective concentrations in the tumor decrease rapidly. By contrast, drug-loaded 
nanocarriers cannot diffuse back into the blood stream because of their large size, 
resulting in progressive accumulation: the EPR effect. B. Active targeting strategies. 
Ligands grafted at the surface of nanocarriers bind to receptors (over)expressed by (1) 




To reduce the tendency of RE system to rapidly phagocytose the nanocarriers, ″steric 
stabilization″ can be employed by applying PEGylation, making it energetically 
unfavourable for other macromolecules to approach. PEGylation is the grafting of 
hydrophilic, flexible poly (ethylene glycol) (PEG) chains to the surface of the 
particulate carrier. The repulsive steric layer reduces the adsorption of opsonins and 
consequently slows down phagocytosis, thus increasing the circulation time.  
Nevertheless, to reach the tumor passively, some limitations exist: (i) The passive 
targeting depends on the degree of tumor vascularisation and angiogenesis. (Bae, 
2009; Danhier et al., 2010). Thus, extravasation of nanocarriers will vary with tumor 
types and anatomical sites. (ii) The high interstitial fluid pressure of solid tumors 
avoids successful uptake and homogenous distribution of drugs in the tumor (Heldin et 
al., 2004). The high interstitial fluid pressure of tumors associated with the poor 
lymphatic drainage explains the size relationship with the EPR effect: larger and long-
circulating nanocarriers (100 nm) are more retained in the tumor, whereas smaller 
molecules easily diffuse (Pirollo and Chang, 2008) (Figure 7A.2). 
 
2.1.5.2 Active targeting 
In active targeting, targeting ligands are attached on the surface of the nanocarrier to 
effectively deliver to a specific cell, tissue or organ (Figure 7B). The ligand is chosen 
to bind to a receptor overexpressed by tumor cells or tumor vasculature and not 
expressed by normal cells. Targeted receptors are expressed homogeneously on all 
targeted cells. Targeting ligands are either monoclonal antibodies (mAbs) and antibody 
fragments or nonantibody ligands (peptidic or not). The binding affinity of the ligands 
to the receptors is an important factor (Adams et al., 2001, Gosk et al., 2008). The 
basic principle of ligand-targeted therapeutics is the specific delivery of drugs to 
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cancer cells. One example of ligand-targeted therapeutics is antibodies (monoclonal 
antibody or fragments) (Figure 8.A) which not only target a specific receptor, but also 
interfere the signal-transduction pathways involved in cancer cells proliferation. 
Hence, these molecules play the role of both targeting as a targeting ligand and 
supplying drug. The examples of such molecules are trastuzumab (anti-ERBB2, 
Herceptin
®
), bevacizumab (anti- VEGF, Avastin
®
) and humanized anti-αvβ3 antibody 
(Abegrin).  
 
Figure 8: Main classes of ligand-targeted therapeutics. A. Targeting antibodies are 
generally monoclonal immunoglobulin g (IgG) (a) or Fab′ fragments (b) or F(ab′)2 
fragments (c). B. Immunoconstructions are formed by the linking of antibodies or 
fragments to therapeutic molecules. C. Targeted nanocarriers are nanocarriers 
presenting targeted ligands at the surface of the nanocarrier. The ligands are either 
monoclonal antibodies and antibody fragments (immuno-nanocarriers) or nonantibody 




When these antibodies (or fragments) are coupled with therapeutic molecules, they 
may only play the role of targeting ligand (Figure 8.B). The first 





), directed against anti-CD-20 (Wiseman et al., 2001). Denileukin diftitox 
(Ontak
®
), an interleukin (IL)-2- diphteria toxin fusion protein, was the first 
immunotoxin received for clinical approval (Duvic et al., 2002). The only clinical 
approved immunoconjugate is gemtuzumab ozogamicin (Mylotarg®) (Jurcic JG, 
2001) (Figure 8.B). Targeted nanocarriers presenting targeted ligands at the surface of 
the nanocarriers contain the cytotoxic drug. The ligands are either monoclonal 
antibodies and antibody fragments (immuno-nanocarriers) (Figure 8.C) or nonantibody 
ligands binding to specific receptors.  
The active targeting strategy can be categorized into two groups: (i) the targeting of 
cancer cell (Figure 7B.1) and (ii) the targeting of tumoral endothelium (Figure 7B.2). 
 
(i) The targeting of cancer cell 
The aim of targeting of cell-surface receptors, overexpressed by cancer cells, is to 
improve the cellular uptake of the nanocarriers. Thus, the selection of proper targeting 
ligands for the endocytosis-prone surface receptors becomes the crucial factor. In fact, 
these actively targeting nanocarriers which enhanced cellular internalization are more 
attractive for the intracellular delivery of macromolecular drugs, such as DNA, siRNA 
and proteins (Kirpotin et al., 2006; Cho et al., 2008). The most common 
internalization-prone receptors, for example, are: (i) the transferrin receptor, (ii) the 
folate receptor, (iii) glycoproteins expressed on cell surfaces (Minko, 2004), and (iv) 
the epidermal growth factor receptor (EGFR) (Scaltriti and Baselga, 2006; Acharya et 
al., 2009;  Lurje and  Lenz, 2009). 
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(ii) The targeting of tumoral endothelium 
The design of nanomedicines actively targeted to tumor endothelial cells is developed 
from the idea that cancer cell growth may be hindered if the blood supply to these cells 
is cut (Folkman, 1971; Lammers et al., 2008). The size and metastatic capabilities of 
tumors can be stunted by attacking the growth of blood vessels which supply blood to 
the cancer cells. Thus, ligand-targeted nanocarriers are developed to bind and kill 
angiogenic blood vessels. In doing so, the tumor cells that these vessels support will 
indirectly be killed. The advantages of the tumoral endothelium targeting are: (i) there 
is no need of extravasation of nanocarriers to arrive to their targeted site, (ii) the 
binding to their receptors is directly possible after intravenous injection, (iii) the 
potential risk of emerging resistance is decreased because of the genetically stability of 
endothelial cells as compared to tumor cells, and (iv) most of endothelial cells markers 
are expressed whatever the tumor type, involving an ubiquitous approach and an 
eventual broad application spectrum (Gosk et al., 2008).  
The main targets of the tumoral endothelium, for example, are: (i) The vascular 
endothelial growth factors (VEGF) and their receptors, VEGFR-1 and VEGFR-2, 
which mediate vital functions in tumor angiogenesis and neovascularisation (Shadidi 
and Sioud, 2003). (ii) The αvβ3 integrin, which is an endothelial cell receptor for 
extracellular matrix proteins which includes fibrinogen (fibrin), vibronectin, 
thrombospondin, osteopontin and fibronectin (Desgrosellier and Cheresh, 2010). (iii) 
Vascular cell adhesion molecule-1 (VCAM-1), which is an immunoglobulin- like 
transmembrane glycoprotein that is expressed on the surface of endothelial tumor cells 
(Dienst et al., 2005). (iv) The matrix metalloproteinases (MMPs), which are a family 




2.2 Alternatives of Drug Formulations 
Conventional chemotherapy delivers anticancer agent non-specifically to cancer cells 
or normal tissues, causing undesirable systemic side-effects. The only way to get a 
drug carrier with low toxicity, high dosage, and localized delivery capability is by 
exploiting the anatomical and pathophysiological abnormalities of cancer tissue. 
Currently, natural and synthetic polymers and lipids are typically used as drug delivery 
system (Peer et al. 2007).  The most common drug delivery systems such as liposomes, 
polymeric nanoparticles, polymer-drug conjugates and polymeric micelles are 
currently developed or under development. The aims of these delivery systems are to 
minimize drug degradation upon administration, prevent undesirable side-effects, and 
increase drug bioavailability and the fraction of the drug accumulated in the 
pathological area (Torchilin, 2010). 
 
2.2.1 Liposmes 
Liposomes are spherical, self-closed structures formed by one or several concentric 
lipid bilayers with inner aqueous phases (Peer et al. 2007). While the internal aqueous 
core is perfectly suited for the delivery of hydrophilic drugs, the phospholipid bilayer 
allows for the encapsulation of hydrophobic chemotherapeutics (New, 1990; Khan et 
al., 2008; Khan, 2010). To date, there are many different methods to prepare liposomes 
of different sizes, structure and size distribution. Cholesterol is used to prepare the 
liposomes (sometimes up to 50% mol) to increase liposome stability towards the action 
of the physiological environment. Depending on size and number of phospholipid 
bilayers, liposomes can be classified into small unilamellar vesicles (SUVs; single 
lipid layer 25 to 50 nm in diameter), large unilamellar vesicles (LUVs; heterogeneous 
group of vesicles), and multilamellar vesicles (MLVs; several lipid layers separated 
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from one another by a layer of aqueous solution) (Sahoo and Labhasetwar, 2003) 
(Figure 9).  
 
Figure 9: Liposomes can vary in size between 50 and 1000 nm. Structures and drug 
loading:  soluble hydrophilic drugs are entrapped into the aqueous interior of the 
liposome (1), while poorly soluble hydrophobic drugs are localized in the liposomal 
membrane (2) (Torchilin, 2010). 
 
Liposomes are biocompatible which cause no or very little antigenic, pyrogenic, 
allergic and toxic reactions. Moreover, they easily undergo biodegradation. In addition, 
they protect the host from any undesirable effects of the encapsulated cytotoxic drug, 
at the same time protecting an entrapped drug from the inactivating action of the 
physiological medium. Liposomes are also capable of delivering their content inside 
many cells (Torchilin, 2010). Their blood circulation time can be increased through 
surface modification (eg, by attaching PEG (Lasic et al., 1999), dextran (Pain, 1984), 
or poly-Nvinylpyrrolidones (Torchilin et al., 2001) to the lipid bilayer). Furthermore, 
conjugation with targeting ligands, like monoclonal antibodies or aptamers, can 
enhance their tissue specificity (Sahoo and Labhasetwar, 2003). Liposomes carrying 
chemotherapeuticdrugs such as doxorubicin (Doxil
®





) have been approved by FDA since the mid-1990s. Liposome 
technology has existed for the past four decades, but they do not have enough market 
share due to some of their potential drawbacks, like low drug loading efficiency, and 
poor stability (Mishra et al., 2010). 
 
2.2.2 Polymeric Micelles 
Micelles are nanoscopic core-shell structures with particle size ranging from 5 to 100 
nm. They are spontaneously formed by self-assembly of amphiphilic or surface-active 
agents (surfactants) at a certain concentration and temperature (Mittal and Lindman, 
1991). At low concentrations, these amphiphilic molecules exist separately as unimers. 
However, at a certain concentration called critical micelle concentration (CMC), these 
molecules start to aggregate and form micelles in which hydrophobic fragments of 
amphiphilic molecules form the core of the micelle. Generally, poorly water-soluble 
pharmaceuticals can be solubilised in the core of micelles and the outer hydrophilic 
layers form a stable dispersion in aqueous media (Lasic, 1992; Muthu and Singh, 
2009). In aqueous systems, nonpolar molecules will be solubilized within the micelle 
core, polar molecules will be adsorbed on the micelle surface, and substances with 
intermediate polarity will be distributed along surfactant molecules in certain 
intermediate positions (Figure 10) (Torchilin, 2010). 
Polymeric micelles are usually put together with amphiphilic block-copolymers of 
hydrophilic PEG and various hydrophobic blocks. Propylene oxide (Miller et al., 
1997), L-lysine (Katayose and Kataoka, 1998), aspartic acid (Harada and Kataoka, 
1998), β-benzoyl-L-aspartate (La et al., 1996), and D, L-lactic acid (Hagan et al., 
1996), for examples, are usually used to build hydrophobic core-forming blocks. In 
most cases, the length of a hydrophobic core-forming block of amphipilic unimers is 
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close to or somewhat lower than that of a hydrophilic PEG block which has molecular 
weight of around 1 to 15kDa (Cammas et al., 1997). Even though there are some other 
hydrophilic polymers which may be used as hydrophilic blocks (Torchilin et al., 1995), 
PEG still remains the corona block of choice. In certain cases, the starting copolymers 
can be prepared from two hydrophilic blocks and then one of those blocks is modified 
by the attachment of a hydrophobic pharmaceutical agent (such as paclitaxel, cisplatin, 
antracyclin antibiotics, hydrophobic diagnostic units, etc.) yielding amphiphilic 
micelle-forming copolymers (Katayose and Kataoka, 1998; Kwon and Kataoka, 1995; 
Trubetskoy et al., 1997). 
 
Figure 10: A micelle as it self-assembles in the aqueous medium from amphiphilic 
unimers (such as polyethylene glycol–phosphatidylethanolamine conjugate, PEG–PE; 
see on the top) with the hydrophobic core (1) and hydrophilic corona (2). In water, 
nonpolar molecules will be solubilised within the micelle core (3), polar molecules 
will be adsorbed on the micelle surface (4), and substances with intermediate polarity 
will be distributed along surfactant molecules in certain intermediate positions (5) 
(Torchilin, 2010). 
 
In some cases, micelles were formulated using PEG attached phospholipid residues 
with two long chains of hydrophobic fatty acyl groups that serve as hydrophobic core-
 27 
 
forming groups (Trubetskoy and Torchilin, 1995). The use of lipid moieties as 
hydrophobic blocks can provide additional advantages for particle stability when 
compared with conventional amphiphilic polymer micelles. For example, diacyllipid–
PEG conjugates (such as PEG–phosphatidyl ethanolamine, PEG–PE) were found to 
form very stable micelles in an aqueous environment with CMC values of 10
-6
 M 
(Kabanov et al., 2002; Torchilin, 2001). Thus, micelles prepared from these polymers 
will maintain their integrity even upon strong dilution (for example, in the blood 
during a therapeutic application). The high stability of polymeric micelles also allows 
for good retention of encapsulated drugs in the solubilized form upon parenteral 
administration. 
As with other nanocarriers used for targeted drug delivery, the drug-delivery potential 
of micelles may be enhanced by conjugating targeting ligands to the water exposed 
termini of hydrophilic blocks (Rammohan et al., 2001; Torchilin, 2010). For example, 
micelles were formulated using amphiphilic PEG-PE with the addition of the small 
fraction of p‑nitrophenylcarbonyl- PEG-PE. The PE forms the hydrophobic core of the 
micelles, whereas p‑nitrophenylcarbonyl enables efficient attachment of targeting 
ligands. Such immunomicelles are found to be, compared with nontargeted micelles, 
capable of delivering higher concentrations of drugs to tumors in mice by an active 
targeting method (Torchilin et al., 2001a; Muthu and Singh, 2009). Moreover, the pH 
at a tumor site is acidic (6.5 to 7.2) compared with that of healthy tissues. Hence, the 
micelles made of pH-sensitive components, such as poly (N-isopropylacrylamide) and 
its copolymers with poly (D,L-lactide) and other blocks, can disintegrate in such areas 






Prodrugs are chemically modified version of the pharmacologically active agents that 
undergo an enzymatic and/or chemical transformation in vivo to release the active 
parent drug, exerting the desired pharmacological effect (Figure 11) (Rautio et al., 
2008). The development of prodrugs is now becoming a well established strategy for 
improving physicochemical, biopharmaceutical or pharmacokinetic properties of 
pharmacologically potent compounds (Beaumont et al., 2003; Stella, 2004; Testa, 
2004). Prodrugs provide possibilities to overcome various barriers to drug formulation 
and delivery such as poor aqueous solubility, chemical instability, insufficient oral 
absorption, rapid pre-systemic metabolism, inadequate brain penetration, toxicity and 
local irritation. Prodrugs can also improve drug targeting. Currently, 5-7% of the drugs 
approved worldwide can be classified as prodrugs (Stella, 2004; Rautio et al., 2008). In 
most cases, prodrugs are simple chemical derivatives that require only a few chemical 
or enzymatic transformation steps to yield the active parent drug (Rautio et al., 2008).  
 
Figure 11: A simplified representative illustration of the prodrug concept. 
The drug-promoiety is the pharmacologically inactive prodrug and the barrier can be 
generally thought of as any limitation of a parent drug that prevents optimal 
pharmaceutical or pharmacokinetic performance. The drug and promoiety are 
covalently linked via bioreversible groups that are chemically or enzymatically labile. 
The ‗ideal‘ prodrug yields the parent drug with high recovery ratios, with the 




A classical example of prodrug with reduced gastrointestinal toxicity and high tumor 
selectivity is capecitabine (Xeloda), which is an orally administered carbamate prodrug 
of the cytotoxic drug, 5-fluorouracil. A cascade of three enzymes is required for the 
bioconversion to the active drug (Figure 12) (Miwa et al., 1998; Testa, 2004; Rautio et 
al., 2008).  
 
 
Figure 12: Capecitabine as an example of a prodrug that requires multiple enzymatic 
activation steps (Testa, 2004; Rautio et al., 2008). 
 
The enzymatic bioconversion pathway initiates in the liver, where human 
carboxylesterases 1 and 2 (CES1 and CES2) cleave the ester bond of the carbamate. 
This is followed by a fast, spontaneous decarboxylation reaction resulting in 5′-
deoxy‑5-fluorocytidine (5′-dFCyd) (Miwa et al., 1998). Generation of the parent drug 
continues in the liver, and to some extent in tumours, by cytidine deaminase (CDA), 
which converts 5′-dFCyd to 5′-deoxyuridine (5′-dFUrd). Finally, thymidine 
phosphorylase (dThdPase; also known as ECGF1) liberates the active drug 
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5′‑fluorouracil in tumours (Testa, 2004; Miwa et al., 1998). Intact capecitabine is 
absorbed from the intestine and undergoes bioconversion in tumours, avoiding any 
systemic toxicity (Miwa et al., 1998). The bioavailability of 5‑FU after oral 
administration of cabecitabine is almost 100% and the Tmax of 5‑FU is reached 
within 1.5–2 hours (Walko and Lindley, 2005).  
 
Figure 13: Ringsdorf‘s model for a polymeric drug containing the drug, solubilising 
groups, and targeting groups bound to a linear polymer backbone (Kratz et al., 2008). 
 
The anticancer drug conjugated with polymer (design proposed by Ringsdorf in 1975) 
has become a fast-growing field, with nearly a dozen polymeric conjugates advancing 
to the clinical trial stage (Ringsdorf, 1975; Li and Wallace, 2008). In Ringsdorf‘s 
postulated model, a drug molecule was bound to a polymeric backbone together with 
solubilising groups and targeting moieties (Figure 13) (Ringsdorf, 1975; Kratz et al., 
2008). In general, polymer-drug conjugates have increased aqueous solubility, 
prolonged plasma circulation half-life and reduced toxicity compared to free drugs 
(Tong and Cheng, 2007). The polymers used in this research field are concentrated 
mainly on N-(2-hydroxypropyl) methacrylamide (HPMA)-based copolymers, 
poly(glutamic acid) (PG) and poly(ethylene glycol) (PEG) as water-soluble drug-
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delivery vehicles (Kratz et al., 2008). Among synthetic polymer-drug conjugates, 
poly(L-glutamic acid) (PG)-paclitaxel (PG-TXL) (CT-2103, Xyotax®) has reached to 
Phase III clinical trials and seemed to be the first of its class to get into the market (Li 
and Wallace, 2008). 
 
2.2.4 Polymeric nanoparticles 
Polymeric nanoparticles are solid and spherical structure with size ranging from 10 to 
1000 nm, in which drugs are encapsulated within the polymer matrix (Torchilin, 2006; 
Muthu and Singh, 2009; Danhier et al., 2010). The term nanoparticles can be divided 
into nanospheres and nanocapsules. In nanospheres, the drug is dispersed throughout 
the particles whereas in nanocapsules, the drug is entrapped in a cavity surrounded by 
a unique polymeric membrane (Allemann et al., 1993; Hillaireau and Couvreur, 2009; 
Danhier et al., 2010). Polymeric nanoparticles are generally synthesized from 
biodegradable polymers - like the poly (lactic acid) (PLA) and poly(lactic-co-glycolic 
acid) (PLGA) polyesters or the poly(alkylcyanoacrylates) (PACA) or natural polymers, 
like albumin. 
 
Figure 14: Principle types of nanocarriers for drug delivery. (A) Liposomes, (B) 
Polymeric nanospheres, (C) Polymeric nanocapsules, (D) Polymeric micelles 
(Hillaireau and Couvreur, 2009). 
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Currently, nanoparticles smaller than 200 nm are extensively investigated to achieve 
efficient passive targeting through EPR effect, avoid complement system activation 
and escape from splenic filtration. Moreover, PEGylation and active targeting with 
antibodies, peptides or cell specific ligands has become essential for efficient drug 
delivery systems (Danhier et al., 2010). PEGylation refers to the conjugation of 
polyethylene glycol to drug delivery systems in order to enhance both the stability and 
circulation time of drug delivery systems (Davis, 2002). The effect of PEGylation can 
also be achieved in drug delivery systems prepared by using diblock or triblock 
copolymers consisting of hydrophilic PEG segment. For example, MPEG-PLGA, 
MPEG-PLA, MPEG-PCL and PLA-TPGS copolymers were synthesized and used to 
fabricate drug nanocarriers to achieve PEGylation effect (Suh et al, 1998; Dong and 
Feng, 2004; Aliabadi et al., 2005; Zhang and Feng, 2006).  
An example of nanoparticles approved by US FDA as a nanomedicine is albumin-
bound paclitaxel (Nab™–paclitaxel), used for treating metastatic breast cancer. This 
nanoparticle formulation does not involve the use of toxic adjuvant Cremophor EL 
unlike traditional paclitaxel formulation. Due to the absence of toxic solvents and the 
albumin receptor mediated delivery, Nab™–paclitaxel tends to provide more 
advantages over traditional solvent-based paclitaxel such as decreased toxicity and 
increased antitumor activity (Stinchcombe, 2007). 
 
2.3 Fabrication Methods of Nanoparticles 
Conventionally, there are two major manufacturing techniques to produce 
nanoparticles. The first technique fabricates nanoparticles by the polymerization of 
monomers, whereas the second synthesizes nanoparticles by the dispersion of 
preformed polymers (Couvreur et al, 1995; Galindo-Rodriguez et al, 2004). An 
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example of the first technique is nanoparticles synthesized by using poly n-butyl 
cyanoacrylate and dextran 70 as a steric stabiliser. It was found that the optimal 
condition for particle fabrication was a dispersion medium of pH 2.5 at a temperature 
of 65˚C (Behan et al., 2001). Even though size, charge and surface morphology of 
nanoparticles synthesized by polymerization of monomers can be tuneable by 
controlling the reaction condition, the processing steps appear to be a bit harsh for 
labile drugs and some residues from the polymerization medium (monomer, oligomer, 
surfactant, etc.) exhibit potential toxic effects (Pinto Reis et al., 2006). Furthermore, 
most of the monomers which are suitable for polymerization process in an aqueous 
phase are non-biodegradable or slowly biodegradable. Hence, to avoid these 
limitations, nanoparticles for drug delivery are usually prepared from preformed 
polymers. Common methods of preparing nanoparticles from preformed polymers are 
emulsion/solvent evaporation, salting-out, solvent displacement and supercritical fluid 
technology (Galindo-Rodriguez et al., 2004; Pinto Reis et al., 2006). 
 
2.3.1 Emulsion/Solvent Evaporation 
There are two types of emulsion/solvent evaporation method, namely oil-in-water 
(o/w) single emulsion and water-in-oil-in-water (w/o/w) double emulsion according to 
the hydrophilicity/hydrophobicity of the encapsulated drug. The simple oil-in-water 
(o/w) emulsion method is used for encapsulation of hydrophobic drug such as 
paclitaxel and docetaxel. In brief, a water-immiscible solution of the polymer and drug 
is emulsified into an aqueous solution containing a stabilizer/surfactant (Yongcheva et 
al., 2003). The crude emulsion is then processed by sonication or high speed/pressure 
homogenization to reduce the droplet size. Finally the organic solvent is removed by 
evaporation or extraction to harden the nano droplets, forming solid particles (Figure 
 34 
 
15) (Wang and Schwendeman, 1999; Pinto Reis et al., 2006). For the encapsulation of 
hydrophilic drugs, water-in-oil-in-water (w/o/w) double emulsion method is applied 
(Thies, 1991; Crotts and Park, 1995; Lee et al., 2007). Firstly, the drug is dissolved in 
water, which is then dispersed in an organic phase containing the polymers. The 
primary emulsion is subsequently emulsified to an aqueous solution in the presence of 
a surfactant. The solid nanoparticles are obtained after solvent evaporation. Water 
immiscible solvent such as chloroform, dichloromethane and ethyl acetate are 
commonly used in this method because they can solubilise the polymers and are 
readily removed by evaporation at ambient temperatures. Poly(vinyl alcohol) (PVA) is 
an excellent emulsifier for NP preparation because it can prevent particle aggregation 
during post-processing (e.g. purification or freeze-drying), and enhance the yield of the 
dry NP product (Quintanar-Guerrero et al., 1998). The size and size distribution of the 
NPs produced by this method are governed by the type and concentration of stabilizer, 
the phase volume ratio and the type of high-energy processing applied during 
preparation (Tice and Gilley, 1985; Yoncheva et al., 2003). For example, paclitaxel-
loaded nanoparticles (Feng et al., 2004), cyclosporine A loaded nanoparticles (Jaiswal 
et al., 2004) and indomethacin loaded nanoparticles (Bodmeier and Chen, 1990) have 
been prepared using this method. 
 
Figure 15: Schematic representation of the emulsion/solvent evaporation technique 





2.3.2 Solvent Displacement 
Solvent displacement method, also called nanoprecipitation method, was developed by 
Fessi et al. in 1989 (Fessi et al, 1989; Quintanar- Guerrero et al., 1998; Letchford and 
Burt, 2007). In this method, the polymer and drug are dissolved in water miscible 
organic solvent like acetone, acetonitrile, tetrafuran, etc. Subsequently, the polymer 
drug solution is poured to the aqueous phase in the presence or absence of a surfactant. 
The interfacial turbulence created due to the rapid diffusion of organic solvent into the 
aqueous phase, led to the formation of nanoparticles (Figure 16) (Fessi et al., 1989; 
Pinto Reis et al., 2006; Letchford and Burt, 2007).  
 
 
Figure 16: Schematic representation of the solvent displacement technique. 
**Surfactant is optional. ***For preparation of nanocapsules. (Pinto Reis et al., 2006) 
 
The advantages of this technique over other techniques are ease of preparation of 
nanoparticles without the need of high energy of sonication and the ability to produce 
small particles size of 200 nm or less (Dong and Feng, 2004; Pinto Reis et al., 2006; 
Dong and Feng, 2007; Cheng et al., 2007). Optimization of the parameters such as 
solvent, non-solvent, polymer and drug concentration are most important in this 
technique to get efficient nanoparticle formulation. In addition, it is essential to use a 
solvent which is not only miscible with aqueous phase but also has the ability to 
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dissolve the polymer and drug (Quintanar- Guerrero et al., 1998; Pinto Reis et al., 
2006). Although the encapsulation efficiency (EE) for hydrophilic drugs is low, 
because of diffusion of the drug molecules within the water-miscible solvent into the 
aqueous phase, the EE of the hydrophobic drugs can be as high as 80% or more (for 
example, cyclosporin A and paclitaxel) (Niwa et al., 1993; Molpeceres et al., 1996; 
Dong and Feng, 2004).  
 
2.3.3 Salting Out 
In the salting out method, the highly saturated electrolyte (magnesium chloride, 
calcium chloride) or non-electrolyte (sucrose) aqueous solution containing poly(vinyl 
alcohol) is added to the acetone solution, in which the polymer and the drug are 
solubilized until a phase inversion occurs and an O/W emulsion is formed (Galindo-
Rodriguez et al., 2004; Pinto Reis et al., 2006).. The oil-in-water emulsion is diluted 
with a sufficient volume of water to facilitate the diffusion of the water-miscible 
organic phase (acetone) to the external phase, leading to the formation of nanoparticles 
(Galindo-Rodriguez et al., 2004; Wischke and Schwendeman, 2008). Excess water and 
salting-out agents are removed by crossflow filtration (Couvreur et al., 1995; De 
Jaeghere et al., 2000; Pinto Reis et al., 2006). Factors that influence the particle size 
include the concentration of stabilizer, the type and concentration of stabilizer, and the 
volume ratio of the oil and water phases (Quintanar- Guerrero et al., 1998; Galindo-
Rodriguez et al., 2004). When compared to previously mentioned methods, saulting 
out method has the advantages of ease of scaling-up and higher drug encapsulation 
efficiency (Quintanar-Guerrero et al., 1998). Moreover, this method does not involve 
hazardous substances or toxic organic solvents in the fabrication process (Allémann et 
al., 1993a; Soppimath et al., 2001).  
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2.3.4 Supercritical (SCF) Technology 
Supercritical (SCF) technology for nanoparticles fabrication is an environment-
friendly technique as it does not involve the use of any toxic organic solvent and 
surfactant. The rapid expansion from supercritical solution (RESS) and supercritical 
anti-solvent precipitation (SAS) techniques are the two most commonly used methods 
for fabrication of nanoparticles (Randolph et al., 1993; Kim et al., 1996; Soppimath et 
al., 2001; Mishra et al., 2010).  
 
Figure 17: Rapid expansion supercritical solution method (Mishra et al., 2010). 
 
In this process, the SCF can be a liquid (eg, water) or gas (eg, carbon dioxide) and 
used above its thermodynamic critical point of temperature and pressure (Mishra et al, 
2010). In the RESS method, the drug and polymer are solubilised in supercritical fluid 
(SCF), which is expanded through a heated nozzle into the low pressure chamber. 
Because of sudden change in temperature and/pressure in new environment, the 
solvent power of SCF is decreased resulting in precipitation of the particles (Figure 17) 
(Jung and Perrut, 2001; Wischke and Schwendeman, 2008). Unfortunately, this 
method cannot be applied for high molecular weight polymers due to very low 
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solubility of SCF (Tom and Debenedetti, 1991; Soppimath et al., 2001; Wischke and 
Schwendeman, 2008).  
In the SAS method, the SCF and the solution containing drug/polymer are separately 
introduced into the precipitating chamber. Antisolvent addition can be carried out from 
the top or bottom of the chamber. At high pressure, fast diffusion of the solvent results 
in supersaturation leading to precipitation of microsized particles with narrow size 
distribution (Figure 18) (Jung and Perrut, 2001; Mishra et al., 2010).  
 
 
Figure 18: Supercritical antisolvent precipitation method (Mishra et al., 2010). 
 
2.4 Lipid Shell and Polymer Core Nanoparticles (LPNPs) 
In the recent years, Lipid shell and polymer core nanoparticles are increasingly gaining 
interest as they combine the merits of both liposomal and nanoparticulate drug delivery 
systems (Chan et al., 2009; Salvador-Morales et al., 2009; Liu et al., 2010). Doxil 
(Doxorubicin encapsulated liposome) was the first to get FDA approval in 1995 for the 
treatment of Kaposi‘s sarcoma and ovarian cancer (Wagner et al., 1994; Gottlieb et al., 
1997; Salvador-Morales et al., 2009). Even though liposomes are highly biocompatible 
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and provide favourable pharmacokinetic profile, they have insufficient drug loading, 
faster drug release and storage instability. On the other hand, nanoparticles can provide 
high drug encapsulation efficiency for hydrophobic drugs and controlled drug released 
profile (Salvador-Morales et al., 2009; Liu et al., 2010). Hence, lipid shell and polymer 
core nanoparticles with antitumor targeting would be an ideal nanocarrier drug 




Figure 19: Schematic illustration of lipid–polymer hybrid nanoparticle (adapted from 
Chan et al., 2009) 
 
Biodegradable polymers such as poly(D,L-lactic acid), poly(D,L-lactic-co-glycolic 
acid) and poly(3-caprolactone) and their co-polymers diblocked or multiblocked with 
polyethylene glycol (PEG) have been commonly used to synthesize nanoparticles to 
encapsulate a variety of therapeutic compounds (Feng, 2006). PEGylation, which 
refers to polyethylene glycol conjugation to drugs or drug carriers, is essential for drug 
delivery devices to enhance both the circulation time and the stability (against enzyme 
attack or immunogenic recognition) (Davis, 2002; Danhier et al., 2010). DSPE-PEG2k 
(N-(carbonyl - methoxypolyethylene glycol - 2000) - 1,2-distearoyl – sn -glycero-3-
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phosphoethanolamine), a lipid attached to PEG, is usually used to coat the outer 
surface of the liposome in order to attain the advantages brought about by PEGylation 
which include prolonged circulation half –life and reduced systemic clearance rates. 
These PEG-end groups can also be functionalized with specific ligands for targeting to 
specific sites of the cells, tissues and organs of interest (Chan et al., 2009; Liu et al., 
2010). An example of lipid shell and polymer core hybrid nanoparticles is shown in 
Figure 19. 
 
2.5 Transferrin/Transferrin Receptor-Mediated Drug Delivery  
By exploiting the particular characteristics of the tumor microenvironment and tumor 
cells, it is possible to design a drug delivery system to specifically deliver the 
anticancer drugs to the cancer cells, thereby, keeping them away from normal cells. 
The target-oriented delivery systems can not only bind the receptors overexpressed by 
cancer cells but also internalize into the cell resulting in direct cell mortality. Examples 
of internalizing-prone receptors are the transferrin receptor, the folate receptor and 
glycoproteins expressed on cell surfaces. The uptake of transferrin (Tf) mechanism has 
been exploited for drugs, proteins and gene delivery into cancer cells that overexpress 
transferrin receptors (TfRs) (Wagner et al., 1994a; Singh, 1999; Vyas and Sihorkar, 
2000; Li and Qian; 2002; Danhier 2010). One of the examples is the Tf-CRM107 
(TransMID, Xenova Group), transferrin conjugated diphtheria toxin, which targets 
brain tumors (Laske, 1994). This Tf-CRM107 is now in phase III clinical trial as phase 
I and II trial have provided encouraging results (Weaver and Laske, 2003). Other 
examples of anti-cancer drugs that have been used in conjunction with Tf include 
doxorubicin, chlorambucil and paclitaxel (Beyer et al., 1998; Wang et al., 2000; Sahoo 
et al., 2004). 
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2.5.1 Properties and Biological Function of Transferrin 
Transferrin is an iron-binding protein, which was discovered more than 40 years ago.  
The transferrin protein contains 679 amino acids and has a molecular weight of about 
79 kDa (Parkkinen et al., 2002).  In human serum, the concentration of transferrin is 
about 2.5 mg/ml with 30% occupied with iron (Leibman and Aisen., 1979). The 
biological of functions of transferrin are:  
- (1) Binding, sequestering, and transporting Fe3+ ions to control the levels of 
free iron in body fluids, regulating iron metabolism and protecting against the 
toxic side effects of free iron (Sun et al., 1999).  
- (2) Antimicrobial activity by withholding the free iron and reducing surface 
adhesion of gram-negative and -positive bacteria (Dalmastri et al., 1988).  
- (3) Important for growth and involved in immune and inflammatory responses 
(Iyer and Lonnerdal, 1993; Lonnerdal and Iyer, 1995).  
 
Figure 20: X-ray crystal structure of human serum transferrin (Li and Qian; 2002).  
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Transferrin protein is divided into two similar lobes, designated the N-lobe and C-lobe, 
which are connected by a short peptide (Figure 20). Each lobe contains two domains of 
similar size, comprising α-helical and β-sheet segments. There is a Fe3+ binding site in 
each lobe. Binding and release of iron induce conformational change which in turn 
affects Tf affinity towards cell receptor. In figure 20, the C-lobe, which contains Fe
3+
 
bound, is shown in a closed form (blue) and the apo N-lobe is in an open form (green). 
 
2.5.2 Structure and Function of Transferrin Receptors 
Human TfR is a transmembrane glycoprotein composed of two disulfide-bonded 
subunits (Trowbridge and Omary, 1981, Schneider et al., 1982).  It contains three N-
linked glycan units (Omary and Trowbridge, 1981; Schneider et al., 1982)  
 
 
Figure 21: X-ray crystal structure of the dimeric ectodomain of the human transferrin 
receptor. (Li and Qian; 2002)  
 
Each TfR monomer binds to one transferrin molecule. The primary receptor 
recognition site of human transferrin is mainly on the C-lobe of transferrin (Zak, 
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1994). However, this has been challenged by recent studies, which show that both C- 
and N-lobe of human serum transferrin are necessary for receptor recognition (Mason 
et al, 1997). Presumably, TfR has conformational changes associated with pH, similar 
to Tf (Figure 21) (Li and Qian; 2002). 
The expression of TfRs is also regulated through the status of cellular proliferation. 
Generally, cells undergoing multiplication distinguishably increase their receptor 
numbers, while nonreplicating cells have a stable iron balance. In malignant cells, 
there are elevated levels of TfR expression attributed to the requirement of high level 
of iron for their growth (Huebers and Finch, 1987). The TfR has been found in red 
blood cells, throid cells, heaptocytes, intestinal cells, monocytes, brain, and the blood–
















CHAPTER 3: SYNTHESIS AND CHARACTERIZATION OF LIPID SHELL AND 
POLYMER CORE NANOPARTICLES 
3.1 Introduction  
Nanoparticles of biodegradable polymer can encapsulate poorly water soluble drugs, 
release drugs at a sustained rate and be further functionalized with targeting ligands for 
targeted drug delivery. Liposomes possess favourable safety profile and ease of surface 
modification. The purpose of development of lipid shell and polymer core 
nanoparticles is to combine the advantages of polymeric nanoparticles and liposomes. 
In this chapter, the effects of different lipids used in nanoparticle preparation on their 
characteristics were studied. Nanoparticles with PLGA as the core and various lipids 
as the shell were produced by nanoprecipitation method. Series of characterization of 
the nanoparticles were carried out by laser light scattering (LLS) for particle size and 
size distribution, zeta potential analyzer for surface charge and field emission scanning 
electron microscopy (FESEM) for surface morphology. The presence of lipid layer on 
the surface of nanoparticles was confirmed by X-ray photoelectron spectroscopy 
(XPS). The structure of lipid shell and polymer core was visualized by transmission 
electron microscopy (TEM). The drug encapsulation efficiency (EE) of the docetaxel-











Docetaxel (anhydrous 99.56%) was purchased from Jinhe Bio-Technology Co. Ltd 
(Shanghai, China). Taxotere
®
 was provided by National Cancer Centre (Singapore). 
Poly [D,L-lactide-co-glycolide] (PLGA, 75:25, Mw: 90,000–126,000), human 
transferrin (Tf), acetone, ethanol, Coumarin 6, propidium iodide (PI),  and sucrose 
were purchased from Sigma-Aldrich (St. Louis, MO,USA). 1,2-distearoyl-snglycero- 
3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPEPEG2k) and 
phosphatidylcholine (PC) were provided by Lipoid GmbH (Ludwigshafen, Germany).  
Triton_ X-100 was provided by Bio-Rad (Bio-Rad Laboratories Inc., USA). All 
solvents such as acetonitrile, ethyl acetate and dichloromethane (DCM) were of High 
Performance Liquid Chromatography (HPLC) grade. All chemicals were used without 
further purification. Millipore water was prepared by a Milli-Q Plus System (Millipore 
Corporation, Breford, USA). 
 
3.3 Methods 
3.3.1 Preparation of Lipid Shell and Polymer Core Nanoparticles (LPNPs) 
The nanoparticles were prepared by the nanoprecipitation method as reported by Chan 
in 2009 and Gan in 2010 with some modification (Chan et al., 2009; Gan and Feng, 
2010). Briefly, 30 mg of PLGA polymer and a designated amount of docetaxel was 
dissolved in 2.55 ml of acetone. While the polymer was dissolved in acetone, 0.45 ml 
of ethanol was added. The polymer/drug solution was then mixed with the aqueous 
phase containing 0.1 wt% lipids (50:50 wt ratio of DSPE-PEG2k and PC) and vortexed 
for 30 seconds. After 4 h, the suspension was washed and centrifuged thrice at 15,000 
g for 20 min each time at 4˚C. For fluorescent coumarin 6-loaded PLGA nanoparticles, 
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the same procedures applied, except that the docetaxel was replaced by 0.05 wt% 
coumarin 6 in organic phase.  
 
3.3.2 Characterization of LPNPs 
3.3.2.1 Particle Size Analysis  
Size and size distribution of the docetaxel loaded PLGA nanoparticles were measured 
by laser light scattering (LLS, 90-PLUS Analyzer, Brookhaven Instruments 
Corporation, TX, USA). The samples were prepared by diluting the nanoparticle 
suspension with deionized water, followed by sonication to prevent particle 
aggregation. The data reported represent the average of six measurements.   
 
3.3.2.2 Surface Morphology  
Surface morphology was imaged by a field emission scanning electron microscopy 
(FESEM) system (JEOL) at an accelerating voltage of 10 kV. Samples for FESEM 
were coated with a platinum layer by JFC-1300 platinum coater (JEOL) for 45 s at 20 
mA before scanning. Transmission electron microscopy (TEM) experiments were 
carried out on a TEM (JEOL, JEM-2010F) instrument at an acceleration voltage of 200 
kV. The TEM sample was prepared by administering the NP suspension on the surface 
of copper grid with carbon film. Samples were blotted away after 10 min incubation 
and grids were negatively stained for 2 min at room temperature with freshly prepared 
and sterile-filtered 2% (w/v) phospho tungstic acid solution. The grids were then 






3.3.2.3  Surface Charge  
Zeta potential of the drug-loaded PLGA nanoparticles was detected by the laser 
Doppler anemometry (Zeta Plus Analyzer, Brookhaven Corporation, USA). The 
particles were suspended in deionized water before measurement. The data were 
obtained as the average of five measurements.  
 
3.3.2.4 Surface Chemistry  
Surface chemistry of lipid shell and polymer core nanoparticles was analyzed by X-ray 
photoelectron spectroscopy (Kratos Ultra DLD, Shimadzu, Japan) under fixed 
transmission mode with binding energy ranging from 0 to 1100 eV and a pass energy 
of 80 eV. 
 
3.3.2.5 Drug Encapsulation Efficiency  
The docetaxel entrapped in the PLGA nanoparticles was measured by HPLC (Agilent 
LC1100, Agilent, Tokyo, Japan). A reverse-phase HPLC column (Agilent Eclipse 
XDB-C18, 4.6 × 250 mm, 5 mm) was used. Briefly, 3 mg of nanoparticles were 
dissolved in 1 ml of DCM. After evaporation, the drug was reconstituted in 1.2 ml of 
mobile phase consisting of acetonitrile and deionized water (50:50, v/v). The solution 
was filtered through 0.45 mm syringe filter before transferring into HPLC vial. The 
flow rate of mobile phase was set at 1.0 ml/min. The column effluent was detected 
with a UV/VIS detector at 230 nm. The calibration curve was linear in the range of 1-
100 ug/ml with a correlation coefficient of R
2 
= 0.995 (Figure 22). The drug 
encapsulation efficiency was defined as the ratio between the amount of docetaxel 





Figure 22: Calibration curve of docetaxel 
 
 
3.3.3  Results and Discussions 
3.3.3.1 Particle Size and Size Distribution 
The characterization of the nanoparticles using different ratio of DSPE-PEG2k and PC 
as emulsifier is summarized in Table 1. The nanoparticles were prepared by 
nanoprecipitation method. As shown in Table 1, the size and polydispersity of 
nanoparticles are increased when the amount of PC used in the nanoparticle 
preparation is increased. This may be because of stabilizing property and bulky nature 
of PC which possesses HLB value of around 13 (Liu et al., 2010). Among 4 different 
types of formulations, docetaxel loaded PLGA/100-0 NPs, PLGA/75-25NPs and 
PLGA/50-50NPs have the particle size smaller than 200 nm which is an ideal size for 
drug delivery systems to escape from the splenic filtration and achieve passive 
targeting via EPR effect (Danhier et al., 2010). Moreover, it has been suggested that 
nanoparticles size range from 100-200nm in diameter can achieve optimum cellular 




Table 1: Size, polydispersity, zeta potential and drug encapsulation efficiency of 
















(1)PLGA/100-0 NPs 157.0 ± 3.0 0.060 ± 0.023 -36.9 ± 10.60 48.5 ± 0.80 
(2)PLGA/75-25 NPs 167.6 ± 1.5 0.153 ± 0.020 -37.0 ± 5.53 55.1 ± 0.40 
(3)PLGA/50-50 NPs 175.7 ± 2.8 0.178 ± 0.015 -34.0 ± 5.10 71.0 ± 1.58 
(4)PLGA/25-75 NPs 267.4 ± 2.9 0.411 ± 0.030 -30.8 ± 5.15 75.5 ± 1.8 
 
PLGA/100-0 NPs, PLGA/75-25 NPs, PLGA/50-50 NPs and PLGA/25-75 NPs denote 
lipid shell and polymer core PLGA nanoparticles synthesized by using 100:0, 75:25, 
50:50 and 25:75 of DSPE-PEG2k and phosphatidyl choline. 
DSPE-PEG2k:1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy 








Actual drug loading % in nanoparticles 
× 100% 
Theoretical drug loading % in nanoparticles 
 
d
Measurement done in deionized water at pH = 7 
 
3.3.3.2 Surface Morphology 
Surface morphology of the LPNPs encapsulating docetaxel was examined by FESEM. 
Figure 23 showed the FESEM images of the docetaxel-loaded LPNPs. All the particles 
were observed to be spherical in shape and seemed to have smooth surface within the 
FESEM resolution level. The FESEM images confirmed the particle size detected from 






    
(A) PLGA/100-0 NPs                 (B) PLGA/75-25 NPs 
    
(C) PLGA/50-50 NPs                (D) PLGA/25-75 NPs 
Figure 23: FESEM images of docetaxel-loaded (A) PLGA/100-0NPs, (B) PLGA/75-




Figure 24: Transmission electron microscopy (TEM) image of PLGA/50-50 NPs 
which were stained with phospho tungstic acid.  
 
The TEM image revealed the core shell structure of LPNPs. Moreover, the 
nanoparticles are dispersed as individual particles with a well-defined spherical shape 




3.3.3.3 Surface Charge 
In terms of nanoparticle stability in colloidal suspension, high absolute value of zeta 
potential (~25 mV or higher) indicated high surface charge of the nanoparticles, 
resulting in a strong repulsive force between particles to stay dispersed from each other 
in nanosuspension (Müller, 1991; Musumeci et al., 2006). So, zeta potentials of all the 
LPNPs are between -30 mV and -40 mV which imply that these LPNPs are stable in 
colloidal system. 
 
3.3.3.4 Surface Chemistry 
 
 
Figure 25: X-ray photoelectron spectroscopy (XPS) peaks of the lipid shell and 
polymer core nanoparticles (PLGA/50-50 NPs). Wide scan spectra (bottom), P 2p 
signal spectra (left inset) were shown in the figure. The existence of lipids coating on 
the surface of the NPs was confirmed via P 2p signals as phosphorous only exists in 
lipid molecules.  
 
X-ray photoelectron spectroscopy (XPS) can be applied to determine the elements or 
components presented on the surface of a compound within a depth range of 1 to 10 
nm. The existence of lipids coating on the surface of the NPs was confirmed via P 2p 




3.3.3.5 Drug Encapsulation Efficiency (EE) 
Different ratios of lipid used in the fabrication of nanoparticles can significantly affect 
the EE of LPNPs. When 100% DSPE-PEG2k was used in the fabrication process, the 
EE of that formulation is smallest compared to other formulations. It can be seen 
clearly that when the amount of PC used in the fabrication of NPs is increased, the EE 
of the NPs is increased. This may be due to increase in viscosity of aqueous medium, 
which decreases the diffusion rate of the solvent.  
  
3.4 Conclusion 
The lipid shell and polymer core nanoparticles were successfully synthesized by 
nanoprecipitation method. The presence of lipid layer on the surface of nanoparticles 
was confirmed by X-ray photoelectron spectroscopy (XPS).The structure of lipid shell 
and polymer core was visualized by transmission electron microscopy (TEM). The 
size, surface charge and encapsulation efficiency of the nanoparticles were found to be 
correlated to the lipid type and quantity. By comparison, PLGA/50-50 NPs gave the 
favourable results, such as high drug encapsulation efficiency and small size 
(<200nm), suggesting the potential to be drug delivery carriers deserving further in 









CHAPTER 4: SYNTHESIS AND CHARACTERIZATION OF TRANSFERRIN 
CONJUGATED LIPID SHELL AND POLYMER CORE NANOPARTICLES 
4.1 Introduction 
PEGylation, passive targeting and active targeting are essential points for the drug 
delivery system to be efficient. Passive targeting can be achieved by exploiting the 
particular characteristics of tumor microvasculature. PEGylation is using of 
hydrophilic polymer (PEG) to coat the nanoparticles surface to achieve the stealth 
property (Danhier et al., 2010). For the active targeting, using of targeting ligands, 
which are targeted to internalization prone receptor such as transferrin receptor or 
folate receptors, are seemed to be more effective. Transferrin, a serum glycoprotein, 
transports iron through the blood and into cells by binding to the transferring receptor 
and subsequently being internalized via receptor-mediated endocytosis (Danhier et al., 
2010). Transferrin receptors are highly expressed in cancer cells as transferrin 
receptors are vital proteins for regulation of cell growth. Transferrin receptor may be 
expressed up to 100-fold higher than the average expression of normal cells (Gomme, 
2005).  In this chapter, the characterization of transferrin-conjugated nanoparticles 
(PLGA/50-50 Tf NPs) was studied together with surface morphology, surface 
chemistry, and in vitro drug release profile. For the targeting purpose, the linker, 












Docetaxel (anhydrous 99.56%) was purchased from Jinhe Bio-Technology Co. Ltd 
(Shanghai, China). Taxotere
®
 was provided by National Cancer Center (Singapore). 
Poly [D,L-lactide-co-glycolide] (PLGA, 75:25, Mw: 90,000–126,000), human 
transferrin (Tf), acetone, ethanol, phosphate buffer saline (PBS), pyridine, 
triethylamine, dicyclohexyl carbodiimide were purchased from Sigma-Aldrich (St. 
Louis, MO,USA). 1,2-distearoyl-snglycero- 3-phosphoethanolamine-N-[methoxy 
(polyethylene glycol)-2000] (DSPE-PEG2k), DSPE and phosphatidylcholine (PC) were 
provided by Lipoid GmbH (Ludwigshafen, Germany).  Poly [ethylene glycol]-bis-
amine was offered by Laysan Bio (Arab, AL, USA). DSPE-PEG-NH2 was synthesized 
by carbodiimide chemistry as previously reported (Lee and Low, 1995; Gabizon et al., 
1999; Wu et al., 2010).   All solvents such as acetonitrile, ethyl acetate and 
dichloromethane (DCM) were of High Performance Liquid Chromatography (HPLC) 
grade. All chemicals were used without further purification. Millipore water was 
prepared by a Milli-Q Plus System (Millipore Corporation, Breford, USA). 
 
4.3 Methods 
4.3.1 Synthesis of DSPE-PEG-NH2  
DSPE-PEG-NH2 was synthesized as reported by Lee in 1995 and Wu in 2010 with 
some modification (Lee and Low, 1995; Wu et al., 2010). N-Succinyl-DSPE was 
synthesized by combining a 1.1 molar equivalent of succinic anhydride, 100 mg DSPE 
in 5 ml chloroform and 10ul pyridine. The mixture was incubated overnight at room 
temperature. Then, the product was precipitated with cold acetone. N-succinyl-DSPE 
was redissolved in chloroform and its carboxyl group was activated by reacting with 
one molar equivalent of dicyclohexyl carbodiimide for 4 hours at room temperature. 
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An equimolar amount of the PEG-bis-amine dissolved in chloroform was then added. 
After overnight stirring at room temperature, the solvent was removed from reaction 
mixture and the product was precipitated with cold acetone. The product was dissolved 
in water to removed the by product, dicyclohexylurea, by centrifugation. The 
supernatant was dialyzed against water. The dialyzed supernatant was lyophilized to 
produce DSPE-PEG-NH2 (Lee and Low, 1995; Wu et al, 2010). The product was 




4.3.2 Preparation of Transferrin Conjugated LPNPs 
The nanoparticles were prepared by the nanoprecipitation method as reported by Chan 
in 2009 and Gan in 2010 with some modification (Chan et al., 2009; Gan and Feng, 
2010). For non-targeted LPNPs, 30 mg of PLGA polymer and a designated amount of 
docetaxel was dissolved in 2.55 ml of acetone. While the polymer was dissolved in 
acetone, 0.45 ml of ethanol was added. The polymer/drug solution was then mixed 
with the aqueous phase containing 0.1 wt% lipids (50:50 wt ratio of DSPE-PEG2k and 
PC) and vortexed for 30 seconds. After 4 hours, the suspension was washed and 
centrifuged thrice at 15,000 g for 20 min each time at 4˚C. For Tf conjugated LPNPs, 
45:45:10 wt ratio of DSPE-PEG2k, PC and DSPE-PEG-NH2 were used to fabricate the 
NPs. Then NPs were collected as the same way and resuspended in PBS (pH 7.4) 
which contain equal molar amount of NHS, EDC and Tf (Gupta et al, 2007; Sun and 
Feng, 2009). The solution was stirred for 4 hours. The Tf-conjugated PLGA 
nanoparticles were recollected by washing and centrifuging the nanoparticle 
suspension for two more times. 
For fluorescent coumarin 6-loaded PLGA nanoparticles, the same procedures applied, 
except that the docetaxel was replaced by 0.05 wt% coumarin 6 in organic phase.  
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4.3.3 Characterization of DSPE-PEG-NH2 
4.3.3.1 
1
H Nuclear Magnetic Resonance (NMR) Spectroscopy 
The synthesis of DSPE-PEG-NH2 is confirmed by 
1
H NMR in CDCl3 on a Bruker 
AMX-500 NMR spectrometer (Bruker Instruments, Billerica, MA, USA) at a 
frequency of 500 MHz. 
 
4.3.4 Characterization of Transferrin Conjugated LPNPs 
4.3.4.1 Particle Size Analysis  
Size and size distribution of the docetaxel loaded PLGA nanoparticles with or without 
Tf conjugation were measured by laser light scattering (LLS, 90-PLUS Analyzer, 
Brookhaven Instruments Corporation, TX, USA). The samples were prepared by 
diluting the nanoparticle suspension with deionized water, followed by sonication to 
prevent particle aggregation. The data reported represent the average of six 
measurements.   
 
4.3.4.2 Surface Morphology  
Surface morphology was imaged by a field emission scanning electron microscopy 
(FESEM) system (JEOL) at an accelerating voltage of 10 kV. Samples for FESEM 
were coated with a platinum layer by JFC-1300 platinum coater (JEOL) for 45 s at 20 
mA before scanning. 
 
4.3.4.3 Surface Charge  
Zeta potential of the drug-loaded PLGA nanoparticles with or without Tf conjugation 
was detected by the laser Doppler anemometry (Zeta Plus Analyzer, Brookhaven 
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Corporation, USA). The particles were suspended in deionized water before 
measurement. The data were obtained with the average of six measurements. 
 
4.3.4.4 Surface Chemistry  
Surface chemistry of PLGA/50-50 NPs and PLGA/50-50 Tf NPs was analyzed by X-
ray photoelectron spectroscopy (Kratos Ultra DLD, Shimadzu, Japan) under fixed 
transmission mode with the binding energy ranged from 0 to 1100 eV and a pass 
energy of 80 eV. 
 
4.3.4.5 Drug Encapsulation Efficiency  
The docetaxel entrapped in the PLGA nanoparticles was measured by HPLC (Agilent 
LC1100, Agilent, Tokyo, Japan). A reverse-phase HPLC column (Agilent Eclipse 
XDB-C18, 4.6 × 250 mm, 5 mm) was used. Briefly, 3 mg of nanoparticles were 
dissolved in 1 ml of DCM. After evaporation, the drug was reconstituted in 1.2 ml of 
mobile phase consisting of acetonitrile and deionized water (50:50, v/v). The solution 
was filtered through 0.45 mm syringe filter before transferring into HPLC vial. The 
flow rate of mobile phase was set at 1.0 ml/min. The column effluent was detected 
with a UV/VIS detector at 230 nm. The calibration curve was linear in the range of 1-
100 ug/ml with a correlation coefficient of R
2 
= 0.995 (Figure 22). The drug 
encapsulation efficiency was defined as the ratio between the amount of docetaxel 







4.3.4.6 In Vitro Drug Release 
Briefly, the drug-loaded NPs were put in a centrifuge tube and dispersed in PBS 
(0.1M, pH 7.4) containing 0.1% w/v Tween-80. Tween-80 was used to increase the 
solubility of docetaxel in the buffer solution and to avoid the binding of docetaxel to 
the tube wall.  Then, the tube was put in an orbital water bath shaking at 120 rpm at 
37˚C. At designated time intervals, the tube was taken out and centrifuged at a speed 
of 10,000 rpm for 15 min. The pellet was resuspended in fresh PBS medium and 
placed back in the water bath for continuous release studies. The samples were 
extracted and analysed according to the same procedures as described in section 
4.3.4.5. All samples were studied in triplicates. 
 
4.4  Results and Discussions 
4.4.1 Characterization of DSPE-PEG-NH2 
4.4.1.1 
1
H Nuclear Magnetic Resonance (NMR) Spectroscopy 
1
H NMR structure of DSPE, NH2-PEG-NH2 and DSPE-PEG-NH2 were shown in 
Figure 26. In 
1
H NMR structure of DSPE, the signal at 1.25 ppm was attributed to 
methylene (-CH2) protons of DSPE (Cheung and Olsona, 1990). That signal can be 
noticed in the 
1
H NMR structure of DSPE-PEG-NH2. In 
1
H NMR structure of NH2-
PEG-NH2, the signal at 3.64 ppm was attributed to the repeated units of PEG, -
OCH2CH2.which is also present in 
1
H NMR structure of DSPE-PEG-NH2. Moreover, a 
new peak around 1.86 ppm was noticed which may be shifted from 2.06ppm peak of 
DSPE. Hence, the synthesis of DSPE-PEG-NH2 was confirmed by 
1
























4.4.2 Particle Size and Size Distribution 
Table 2: Size, polydispersity and zeta potential of docetaxel-loaded PLGA/50-50 NPs 
and PLGA/50-50 Tf NPs 
 PLGA/50-50 NPs PLGA/50-50 Tf  NPs 
Size
a
 (nm) 175.7±2.8 nm 190.6±7.9 nm 
Polydispersity
a
 0.178±0.015 0.125±0.031 
Zeta potential
a,b




Measurement done in deionized water at pH = 7 
 
In general, the sizes of the two formulations are smaller than 200 nm, which is an 
optimal size for drug delivery system (Table 2). Including the DSPE-PEG-NH2 
together with targeting ligand transferrin in the formulation of nanoparticles can 
increase the hydrodynamic diameter of the LPNPs.   
 
4.4.3 Surface Morphology 
  
  (A)      (B) 
Figure.27. FESEM images of docetaxel-loaded   (A) PLGA/50-50 NPs and (B) 
PLGA/50-50 Tf NPs.  
 
Figure 27 shows the FESEM images of the docetaxel PLGA/50-50 NPs and PLGA/50-
50 Tf NPs. All the particles were observed to be spherical in shape and seemed to have 
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smooth surface within the FESEM resolution level. The FESEM images confirmed the 
particle size and polydispersity value detected from the LLS. 
 
4.4.4 Surface Charge 
The zeta potentials of both PLGA/50-50 NPs and PLGA/50-50 Tf NPs are between     
-30 mV and -40mV (Table 2). Because of higher static charge on the surface of the 
nanoparticles, it can be assumed that nanoparticles would be stable in colloidal system 
(Müller, 1991; Musumeci et al., 2006). 
 
4.4.5 Surface Chemistry 
 
 
Figure 28: X-ray photoelectron spectroscopy (XPS) peaks of PLGA/50-50 NPs and 
PLGA/50-50 Tf NPs. Wide scan spectra (bottom) and N1s signal spectra (right insert) 
were shown in the figure.  
 
The existence of Tf on the surface of the NPs was confirmed by comparing the 
intensity of nitrogen signal from PLGA/50-50 NPs and PLGA/50-50 Tf NPs (Figure 
28). The obvious peak (~399 eV) in high resolution scan (insert) of the N binding 
energy region attributed to the 1s orbital of N atom. The signal was result of the 
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nitrogen element of the conjugated-transferrin on the surface of the targeted 
nanoparticles (Gan and Feng, 2010). 
 
4.4.6 Drug Encapsulation Efficiency 
The drug encapsulation efficiency of PLGA/50-50 NPs and PLAG/50-50 Tf NPs are 
71.0 ± 1.58 % and 67.7 ± 2.19 % respectively (P>0.05). Therefore, the combination of 
DSPE-PEG-NH2 as a linker for conjugation of Tf during NPs fabrication process does 
not significantly affect the drug encapsulation efficiency of nanoparticle formulations.  
 




Figure 29: In vitro drug release profiles of the PLGA/50-50 NPs and PLGA/50-50 Tf 
NPs in pH 7.4 PBS buffer at 37˚C.  
 
Figure 29 shows the drug release profiles of docetaxel from the drug loaded PLGA/50-
50 NPs and PLGA/50-50 Tf NPs in 28 days. Docetaxel was released from the 
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nanoparticles in a pH 7.4 PBS buffer at 37˚C. From the figure, it can be seen that 
docetaxel was released in a biphasic style with an initial burst and subsequent 
accumulative release (Sun and Feng, 2009). Figure shows that the initial bursts of 
PLGA/50-50 NPs and PLGA/50-50 Tf NPs within the first day are 26.81±0.13% and 
21.50±0.36% respectively. And 28-day cumulative drug releases of these particles are 
98.52±0.90% and 96.91±2.14% respectively. The initial burst is due to the certain 
amount of docetaxel attached on the surface of the nanoparticles which is helpful to 
suppress the growth of cancer cells in short time (Liu et al., 2010).  Moreover, 5-day 
cumulative releases of these particles are more than 60%, and the releases present 
sustained increased manner, which may be more effective for killing cancer cells. The 
cumulative release percent of both particles reached more than 90% after 14 days. The 
faster drug release may be due to the strong interaction between lipid molecules and 
drug molecules, leading to diffusion of drug molecules from PLGA matrix. In 
addition, permeation of the water molecules into lipid shell of nanoparticles can also 
lead to faster drug release. From these data it can be concluded that the nanoparticles 
formulations can provide sustained and controlled drug release profile for the delivery 
of anticancer drugs (Liu et al., 2010). 
 
4.5 Conclusion 
Transferrin conjugated lipid shell and polymer core nanoparticles were successfully 
synthesized by nanoprecipitation method. The sizes of both targeted and non-targeted 
nanoparticles formulations were smaller than 200 nm. The surface morphology of 
nanoparticles was observed by FESEM and was found to have smooth surface. 
Moreover, EE of both targeted and non-targeted nanoparticles are around 70%, 
suggesting an effective carrier for drug delivery. The presence of transferin on the 
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surface of the nanoparticles was also confirmed by XPS spectra, showing N signal 
from the transferrin. For the drug release behaviors of the NPs, both nanoparticles 
formulations could provide sustained and controlled release of docetaxel for the 




























Specific tumor targeting is aimed to achieve better profiles of pharmacokinetics and 
pharmacodynamics, improved specificity to certain cancer cell type, increased cellular 
internalization and intracellular delivery and lower systemic toxicity (Danhier et al., 
2010). In fact, the proper targeting ligands, the specific cellular markers for the 
diseased cells, the proper type of therapeutic drug to treat the disease effectively and 
the way to carry the drug to the target are some of the challenging factors in targeting 
(Bae, 2009; Danhier et al., 2010). Active targeting can be achieved by using proper 
targeting ligands, which can lead to enhanced cellular internalization and intracellular 
drug delivery through receptor-mediated endocytosis. In this chapter, in vitro studies 
such as the cellular uptake, cell imaging using confocal laser scanning microscope and 
cell viability were performed. To compare the effect of active targeting in terms of 
uptake efficiency and cell cytotoxicity, transferrin conjugated and non-conjugated 
nanoparticles were employed. In addition, commercial formulation Taxotere
®
 was also 
used in cell cytotoxicity study to evaluate some of the advantages of using equivalent 
drug-loaded nanoparticle formulation over the clinical formulation. Human breast 









Phosphate buffer saline (PBS), coumarin 6, propidium iodide (PI), 3-(4,5-
dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, tripsin-EDTA 
solution and sucrose were purchased from Sigma-Aldrich (St. Louis, MO,USA). Fetal 
bovine serum (FBS) was purchased from Gibco Life Technologies (AG, Switzerland). 
Penicillin-streptomycin solution was from Invitrogen. Dulbecco‘s Modified Eagle‘s 
Medium (DMEM) was from Sigma. MCF7 breast cancer cells were provided by 
American Type Culture Collection (ATCC).  All solvents such as ethanol, isopropanol, 
DMSO and sodium hydroxide were from Sigma-Aldrich. All chemicals were used 
without further purification. Millipore water was prepared by a Milli-Q Plus System 
(Millipore Corporation, Breford, USA). 
 
5.3 Methods 
5.3.1  Cell Culture 
Human breast adenocarcinoma MCF7 (American Type Culture Collection, USA) were 
cultured in DMEM medium supplemented with 10% FBS and 1% penicillin-
streptomycin and incubated in SANYO CO2 incubator at 37°C in a humidified 
environment of 5% CO2. The medium was replenished every 1 - 2 days until 
confluence was reached. The cells were then washed twice with PBS and harvested 
with 0.125% of trypsin-EDTA solution. 
 
5.3.2 In Vitro Cellular Uptake  
For quantitative study, confluent MCF7 cell lines were seeded into 96 well assay plates 
(Corning Incorporated) at 1.0 × 10
4
 viable cells/well. After the cells reached about 70-
80% confluence, the cells were incubated with 250 µg/ml coumarin 6-loaded 
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nanoparticles in the Dubelco‘s Modified Eagle‘s Medium (DMEM, Sigma) 
supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin at 37˚C for 
2 h and 4 h. Competitive effect of endocytosis was also studied by pre-incubating the 
cells with excess free Tf (200 µg/ml) before incubating with PLGA/50-50 Tf NPs. At 
designated time interval, the suspension was removed and the wells were washed three 
times with 50 µl cold PBS. After that, 50 µl of 0.5% Triton X-100 in 0.2 N NaOH was 
introduced into each well for cell lysis. The fluorescence intensity of each sample well 
was detected by the Tecan microplate reader (GENios) with excitation wavelength at 
430 nm and emission wavelength at 485 nm. Cell uptake efficiency was expressed as 
the percentage of cells-associated fluorescence after washing versus the fluorescence 
present in the feed suspension. 
For the qualitative study, cells were seeded in LABTEK
®
 cover glass chambers (Nagle 
Nunc) at a concentration of 6000 cells/chamber. The cells were incubated overnight 
and were subsequently incubated with 250 µg/ml coumarin 6-loaded nanoparticles at 
37˚C. For the competitive effect of Tf, an excess of free Tf (200 µg/ ml) were 
incubated with the cells 1 h prior to cell uptake of nanoparticles. After 2 h, the cells 
were washed 3 times with cold PBS and fixed by 75% ethanol for 20 min. Then, the 
cells were washed twice with cold PBS. The nuclei were stained by incubating with 
propidium iodide (PI, Sigma) for another 40 min. The cells were washed three times 
with PBS and observed by confocal laser scanning microscopy (CLSM) (Nikon C1, 







5.3.3  In Vitro Cell Cytotoxicity   
Cancer cell viability of the docetaxel-loaded PLGA/50-50 NPs and PLGA/50-50 Tf 
NPs was investigated by the MTT assay.100 µl of MCF7 cells were seeded into 96 
well plates (Costar, IL, USA) at the density of 5×10
3
 viable cells/well and incubated at 
least overnight to allow cell attachment. The spent medium was discarded and the cells 
were incubated with the docetaxel-loaded nanoparticle suspensions in comparison with 
Taxotere
®
 at 0.025, 0.25 and 2.50 µg/ml equivalent of docetaxel concentration for 24 
and 48 h respectively. At designated time points, the medium was removed and the 
wells were washed twice with cold PBS. Following that, 100 µl of MTT solution was 
added to each well of the plate. The plates were further incubated for 3-4 h in the 
incubator. Finally, 50 µl of DMSO was added into each well of transformed MTT 
crystals and the absorbance of the transformed MTT solution in the wells was 
measured at 450 nm wavelength using a microplate reader. Cell viability was 
expressed by the ratio between the fluorescence intensity of the cells incubated with 
NPs (or Taxotere
®
) and that of the cells incubated with culture medium only. IC50, the 
drug concentration at which inhibition of 50% cell growth was observed in comparison 
with that of the control sample, was calculated from the cell viability versus the drug 
concentration curve at a given period say 24 h. 
 
5.4 Results and Discussions 
5.4.1 In Vitro Cell Uptake 
Quantitative analysis of cellular uptake was shown in Figure 30. It can be noticed from 
figure that there was a trend of general increase of nanoparticle uptake by the cells 
with the incubation time. The time-dependent behaviour of the uptake could be 
explained by the presence of active endocytosis process within the system. PLGA/50-
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50 Tf NPs show significantly higher cellular uptake than non-targeted nanoparticles 
after 4 h incubation (P<0.05). On the other hand, when an excess of free Tf was pre-
incubated with the cells before incubation with the PLGA/50-50 Tf NPs, the uptake of 
PLGA/50-50 Tf NPswas suppressed. Therefore, the inhibitory effect of the excess free 
Tf confirmed the existence of additional Tf receptor mediated endocytosis (RME), 




Figure 30: Cellular uptake of coumarin 6-loaded PLGA/50-50 NPs and PLGA/50-50 
Tf NPs incubated with MCF7 breast cancer cells at 37˚ C for 2 h and 4 h. 
 
Figure 31 shows the confocal images of MCF7 cells after incubation with the various 
NPs formulations. To better compare the intensity of fluorescence between the cells 
treated with the various NPs formulations, the images were taken by keeping the 
parameters such as sensitivity, gain, offset, and laser power constant throughout the 
cell imaging process. It can be observed that the green fluorescence from Row 2, 
which corresponds to the coumarin 6-loaded PLGA/50-50 Tf NPs, was slightly 
stronger than that of PLGA/50-50 NPs (Row 1). In addition, the images in Row 3 
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represent the cells pre-incubated with excess free Tf 1 h before the cells were 
incubated with the PLGA/50-50 Tf NPs suspension. As the fluorescence intensity was 
qualitatively comparable to that of the PLGA/50-50 NPs, it can be explained that there 
was a competitive effect from free Tf, which results in a relatively lower 




Figure 31:.Confocal laser scanning microscopic images of MCF7 breast cancer cells 
after 2 h incubation with coumarin 6-loaded nanoparticles. Column A: FITC channels 
showing the green fluorescence from coumarin-6 loaded nanoparticles distributed in 
cytoplasm. Column B: PI channels showing the red fluorescence from propidium 
iodide stained nuclei. Column C: Merged channels of FITC and PI channels. Row 1 
and 2 show the uptake of PLGA/50-50 NPs and PLGA/50-50 Tf NPs respectively. 
Row 3 shows the uptake of the same PLGA/50-50 Tf NPs as row 2 but 1 h incubation 
of free Tf before PLGA/50-50Tf NPs.  
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Figure 32: In vitro cell viability test of docetaxel loaded PLGA/50-50 NPs, PLGA/50-
50 Tf NPs and Taxotere
®
 incubated with MCF7 breast cancer cells at 37 C for 24 h (A) 
and 48 h (B). 
 
In vitro cytotoxicity of docetaxel loaded nanoparticles with or without Tf conjugation 
on their surface was investigated with MCF7 cells after 24 h and 48 h incubation at 
37˚C and the results are shown in Figure 32. For both 24 h and 48 h study, PLGA/50-
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50 Tf NPs formulation provides the lower cell viability than PLGA/50-50 NPs 
formulation and the commercial Taxotere
®
 in all equivalent drug concentration levels 
applied. This is because of the internalization of nanoparticles through the Tf/Tf 
receptor specific binding activity, delivering more drugs into cell cytoplasm directly.  
 
Table 3: IC50 of MCF7 cells after 24 and 48 h incubation with docetaxel formulated in 
PLGA/50-50 NPs formulation, PLGA/50-50 Tf NPs formulation and Taxotere
®
 at 
various drug concentrations. 
 
 
IC 50 after 
24 h 
incubation 
IC 50 after 
48 h 
incubation 






 11.38±5.87 0.53±0.27 
 
Table 3 shows the IC50, which is the drug concentration required to induce the death of 
50% cell incubated in a designated period, of PLGA/50-50 NPs, PLGA/50-50 Tf NPs 
and Taxotere
®
. For instance, after 24 h and 48 h incubation, IC50 for PLGA/50-50 Tf 
NPs were much lower than those of non-targeted nanoparticle formulation and 
commercial drug Taxotere
®
 formulation. This indicates that in order to kill the same 
number of cancer cells, the targeted NPs formulation may require much lower drug 
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Cellular uptake study of coumarin 6-loaded PLGA/50-50 NPs and PLGA/50-50 Tf 
NPs demonstrated that the uptake efficiency of both types of NPs was increased with 
time. This is because of the presence of non-specific endocytic uptake mechanism of 
NPs. In addition to that, the uptake efficiency of transferrin conjugated nanoparticles 
was much higher than those of non targeted nanoparitcles, confirming the existence of 
receptor-mediated endocytosis mechanism. However, when the cells are already 
incubated with Tf, the uptake of the transferrin conjugated NPs become more or less 
the same with those of the non targeted nanoparticles, showing the competitive effect 
from free Tf. These quantitative study results can be confirmed with confocal 
microscopy. Furthermore, the transferrin conjugated nanoparticles provide higher cell 












CHAPTER 6: IN VIVO PHARMACOKINETICS, COMPLETE BLOOD COUNT 
AND BLOOD BIOCHEMISTRY STUDY 
 
6.1 Introduction 
In this chapter, in vivo pharmacokinetics, complete blood count and blood chemistry 
study were performed to evaluate the nanoparticle formulation for efficacy and safety 
as compared to the commercial drug Taxotere
®
. The purpose of doing in vivo 
pharmacokinetics was to study the long circulation effect of nanoparticles in rats. 
Complete blood count analysis and serum chemistry were studied to assess the toxicity 


















6.2 Materials and Methods 
6.2.1 In Vivo Pharmacokinetics 
Male Sprague-Dawley (SD) rats of 130-180 g (or 4-5 weeks old) were supplied by the 
Laboratory Animals Centre of Singapore. The animals were maintained at Vivarium at 
the Centre of Life Science (CeLS) of National University of Singapore. The animal 
caring, handling, husbandry and the protocols were approved by the Institutional 
Animal Care and Use Committee (IACUC), Office of Life Science, National 
University of Singapore. The animals were acclimatized at a temperature of 25±2 ˚C 
and a relative humidity of 50-60% under natural light/dark conditions for 4-5 days 
before experiments. 
The animals were randomly distributed into two groups with five rats in each group. 
Group 1 received an i.v. injection of the commercial drug Taxotere
®
 formulation while 
Group 2 received an i.v. injection of the PLGA/50-50 NPs formulations. The docetaxel 
loaded NPs formulations were dispersed or diluted with 0.9 wt% NaCl saline while 
maintaining the volume to be injected at 5 ml/kg rat/site. The formulation was 
subsequently administered through the lateral tail vein at docetaxel dose of 7.5 mg/kg 
body weight. All animals were regularly monitored for their general health condition, 
clinical signs, stress, movement and activity or mortality. Small amount of blood was 
drawn from the rats in each group through tail vein at designated intervals till day 7 of 
injection. 
Plasma samples were harvested by centrifugation at 8,000 rpm for 10 min and stored at 
-80°C for future processing. Plasma liquid-liquid extraction was performed using ethyl 
acetate (EA, Sigma Aldrich). The organic layer was separated by centrifugation and 
dried under reduced pressure. Dried samples were reconstituted in ACN: water 50: 50 
v/v for HPLC analysis. Then, the elution gradient was from 100% mobile phase B 
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(ACN: methanol: water 40: 5: 50 v/v/v) to 100% A (45: 5: 50 v/v/v) in 50 min at a 
flow rate of 1.0 ml/min. The drug content of the samples was then calculated based on 
the pre-established calibration curve using blank plasma. Assuming a non-
compartmental model, some pharmacokinetic parameters were calculated by Kinetica 
software (Gan et al., 2010). 
 
6.2.2 Complete Blood Count 
For complete blood count (CBC) test, the blood from tail vein was collected in BD 
Vacutainer
®
 blood collection tube containing EDTA at day 3 and day 7 of injection. 
Blood of about 1 ml volume was collected and mixed to prevent blood clotting. The 
collected blood was tested using CELL-DYN
®
 3700. The instrument was calibrated 
using internal standards. 
 
6.2.3 Blood Biochemistry Study 
For the purpose of serum chemistry analysis, the blood was collected in BD 
Vacutainer
®
 blood collection tube containing Heparin and stored at 4
o
C at day 3 and 
day 7 of injection. The tubes were centrifuged at 4000 rpm for 10 minutes. The 
separated plasma was isolated and analyzed using cobas c 111 analyzer (Roche). 
Spectrophotometer assay is performed using internally loaded serum chemistry 
standards (Roche). The values from the assay were compared to those of the normal 
one. 
 
6.2.4 Histopathological evaluation  
Perfusion of rats injected by PLGA/50-50 NPs and non-injected rats was done using 
0.1 M Ringer‘s buffer solution for 5 min, followed by 2% paraformaldehyde fixative 
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for 20 min. The liver and kidney were extracted and immersed in the same fixative 
solution for 3 h. Then, the samples were placed into 20% sucrose solution overnight. 
The liver and kidney were embedded in Tissue-Tek
®
 optimum cutting temperature 
(O.C.T.) compound (Thermo Fischer Scientific, USA) on a specimen disc and cryo-
freezed immediately in liquid nitrogen. Subsequent sectioning with microtome 
(Cryostat, Leica CM3050s, Germany) into sections of 20 µm thickness was performed. 
The sections were placed onto the gelatin-coated microscopic slides for drying (Gan 
and Feng; 2010). The tissue sections were stained by Haematoxylin and Eosin (H&E) 
staining. Then, a veterinary pathologist was consulted to evaluate any sign of toxicity 
in these liver and kidneys histology slides. The tissue sections were imaged under 
Olympus BX51/Microscope Digital Camera System DP50 microscope. 
 
6.3 Results and Discussions 
6.3.1  In Vivo Pharmacokinetics 
Pharmacokinetics of the docetaxel loaded PLGA/50-50 NPs and the commercial 
Taxotere
®
 was evaluated by using SD rats at the dose of 7.5 mg/kg. Mean non-
compartmental pharmacokinetic parameters of SD rats were analysed by Kinetica 
software and shown in Table 4. The area-under-the-curve (AUC) is a quantitative 
measurement of the in vivo therapeutic effect of a drug formulation. The AUC of 
PLGA/50-50 NPs is more than 2 times larger than those of Taxotere
®
 (P<0.05). 
Likewise, T1/2 of PLGA/50-50 NPs formulation is 4 times larger than those of 
Taxotere
®





 Maximal tolerated level 
   Minimal effective level 
 
Figure 33: In vivo pharmacokinetics profiles of docetaxel plasma concentration vs. 
time after i.v. administration of Taxotere
®
 and the PLGA/50-50 NPs formulation using 
Sprague-Dawley rats at the same docetaxel dose of 7.5 mg/kg (n=5). 
 
Table 4: Mean non-compartmental pharmacokinetic parameters of SD rats for 
intravenous administration of Taxotere
®














T1/2 (h) 3.91±0.12 15.60±0.41 
MRT (h) 4.53±0.37 21.08±1.10 
CL (ml/h/kg) 121.93±11.52 58.83±3.73 
 
AUC is the area under concentration-time curve 
T1/2 is the biological half-life 
MRT stands for mean residence time 




From Figure 33, it is cleared that both drugs were within therapeutic windows, and 
docetaxel from nanoparticles formulation can last up to 3 days whereas those of 
Taxotere
®
 only last for 24 h (Gan et al., 2010). Long circulation time of PLGA/50-50 
NPs may be due to the stealth property of DSPE-PEG2K. In short, the docetaxel loaded 
lipid shell and polymer core nanoparticles successfully produced higher AUC, offering 
an improved therapeutic index compared with Taxotere
®
 (Zhao et al., 2010). 
 
6.3.2 Complete Blood Count 
Table 5: Complete blood count for SD rats after intravenous administration of 
Taxotere 
®
 and PLGA/50-50 NPs at a dose of 7.5 mg/kg, and for rats receiving no 


















WBC (K/ul) 12.7 ± 1.3 5.9 ± 0.7 8.4 ± 1.8 10.6 ±3.6 13.8 ± 5.0 
Neutrophil 
Count (K/ul) 
1.0 ± 0.1 0.6± 0.4 1.6 ± 0.3 1.3 ± 0.2 1.3 ± 0.6 












HGB (g/dl) 14.0 ± 0.1 12.4 ± 0.5 13.6 ± 0.7 14.3 ± 0.6 14.6 ± 0.7 
 
Table 5 shows the complete blood count analysis of  rats after day 3 and day 7 i.v 
administration of Taxotere
®
 and PLGA/50-50 NPs. Complete blood count analysis 
included WBC, RBC, platelet and HGB. From Table 5, it is clear that WBC and 
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neutriphil count of rats after day 3 injection of Taxotere
®
 is significantly lower than 
those of PLGA/50-50 NPs formulation (P<0.05). Even though the same dosage of 
docetaxel is used for both PLGA/50-50 NPs and Taxotere
®
 formulation, toxicity 
suffered by host is different. For PLGA/50-50 NPs injection, the drugs are 
encapsulated within the nanoparticles, preventing the direct contact of drugs with the 
blood and body fluids, whereas for Taxotere
®
, most of the normal tissues are exposed 
to drugs resulting in side effects (Zhao et al., 2010). Bone marrow suppression is one 
of the common side-effects of Taxotere
®
. Hence, it can be concluded that PLGA/50-50 




6.3.3 Blood Biochemistry Study 
Generally, ALT, AST, ALP and bilirubin are used to measure to test the liver function 
whereas creatinine is used to check for kidney function. Table 6 shows the results of 
liver function and kidney function tests. Here, all the parameters were within normal 
limit. Therefore, both PLGA/50-50 NPs and Taxotere
®
 formulation did not show 











Table 6: Serum chemistry for SD rats after intravenous administration of Taxotere
®
 





















273.4 189.3±58.8 270.2±42.1 185.9±45.3 210.7±37.8 
AST (U/L) 
(63-127) 
59.2 93.6±9.7 117.3±13.8 75.8±3.8 104.1±14.8 
ALT(U/L) 
(35-80) 








0.2 N.A N.A 0.2 0.2 
ALP - alkaline phosphatase 
AST - aspartate transaminase  
ALT - alanine transaminase 







6.3.4 Histopathological evaluation  
  
Figure 34: Representative H&E stained tissue sections of rat liver and kidney obtained 
from non-injected animals (top row) and from those injected with docetaxel loaded 
PLGA/50-50 NPs (7.5 mg/kg) (bottom row).  
Histopathological evaluation of liver and kidney was performed to identify the sign of 
toxicity (Figure 34). Tissue sections reviewed by a veterinary pathologist showed no 
evidence of toxicity, appearing similar to those observed from non-injected control 
animals. Therefore, results from histopathology and serum chemistry indicated that the 




In vivo pharmacokinetic study shows that our nanoparticles can last longer in the blood 
circulation compared to commercial drug Taxotere
®
.  Longer circulation time of 
PLGA/50-50 NPs formulation is due to the presence of PEG on the surface of the 
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nanoparticles. Moreover, from the complete blood count study, the docetaxel loaded 
PLGA/50-50 NPs formulation shows greater advantages over Taxotere
®
 as less drug is 
exposed to normal tissues in nanoparticle formulation, thereby causing less side effect. 
Toxicity assessment of liver and kidneys was also performed by doing liver function 
test and kidney function test. All the parameters of the serum chemistry results are 
within normal limit. Hence, together with histopathology, it can be concluded that no 





















CHAPTER 7: CONCLUSIONS AND RECOMMENDATIONS 
 
7.1 Conclusions 
The transferrin conjugated lipid shell and polymer core nanoparticles formulation for 
the delivery of anticancer drug docetaxel was successfully developed. The main idea 
was based on achieving a nanocarrier which has combined advantages of both 
liposomes and polymeric drug delivery system. Even though nanoparticles can reach 
tumors by EPR effect, a ligand may require to efficiently internalize the nanoparticles 
into the cells. Therefore, transferrin conjugated nanoparticle formulation was 
developed and series of studies were done to prove its potential as a promising drug 
carrier. 
Chapter 1 and 2 of the thesis provide objectives and general background of the project. 
Then, in Chapter 3, the fabrication and characterization of lipid shell and poly core 
nanoparticle formulations were described. Following that, formulation of transferrin 
targeted lipid shell and polymer core nanoparticles was described in Chapter 4. The 
NPs were further evaluated in Chapter 5 using human breast cancer cell line MCF7 as 
an in vitro model. PLGA/50-50 Tf NPs showed greater cellular uptake than non 
targeted particles. Furthermore, cell viability test was performed in comparison with 
Taxotere
®
 and non targeted nanoparticle formulation, PLGA/50-50 NPs.  Lastly, the 
animal study, in Chapter 6, demonstrated that pharmacokinetic profile of docetaxel 
loaded nanoparticles was better than those of Taxotere
®
. Moreover, from the complete 
blood count study, our nanoparticles formulation showed lesser side effects than those 
of Taxotere
®
.  Toxicity assessment of liver and kidney was also performed by doing 
blood biochemistry tests. These findings were further confirmed by histological 
evaluation.  Finally, it can thus be concluded that lipid shell and polymer core 
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nanoparticles formulation can serve as an efficient and safe drug delivery system for 
anticancer drug delivery.  
 
7.2 Recommendations 
The goal of novel anticancer drug design is to selectively target and kill the cancer 
cells, improving therapeutic efficacy while minimizing the side effects. 
Nanotechnology is one of the most promising approaches to achieve this goal. In this 
project, in vitro cell work and in vivo study were performed and the results obtained 
showed the lipid shell and polymer core nanoparticles formulation as a feasible drug 
delivery system. Therefore, the future works that may improve the current work 
included the following:  
(i) Development of xenograft tumor models to evaluate the efficiency of targeted 
delivery system.  
(ii) Toxicity assay should be performed with different dosage regimes, in order to 
understand the safety profile of the nanoparticulate drug delivery system. 
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